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ABSTRACT 
 
 
 Hox genes encode transcription factors that play essential roles in the correct 
establishment of skeletal morphology of the axial and limb skeleton during embryonic 
development. Despite continuous expression throughout the life of an animal, Hox genes 
have largely been studied in the context of embryogenesis and there continues to be a dearth 
of information regarding their functional significance at adult stages after the skeleton has 
been established. Here, I have used Hox11 as a model to investigate outstanding questions 
regarding Hox gene function in the adult mammalian skeleton. 
Hox11 expression within the limb skeleton is restricted to the zeugopod of the 
forelimb (radius/ulna) and hindlimb (tibia/fibula). It is indispensable for the proper 
development of the zeugopod as the loss of Hox11 function results in the complete 
malformation of those skeletal elements. In the adult, Hox11 expression is exclusive to a 
progenitor-enriched mesenchymal stem/stromal cell (MSC) population in the adult bone. 
Lineage analysis revealed that the Hox11-expressing MSC population establishes during 
embryonic development, exhibits self-renewal, and gives rise to all mesenchymal lineages 
within the skeleton—osteoblasts, osteocytes, chondrocytes, and bone marrow 
adipocytes—throughout the life of an animal. While these studies provided information 
regarding the cellular contribution of Hox-expressing cells,  they do not address whether 
Hox function is required at later stages. Continuing functions for Hox beyond embryonic 
development have been suggested by studies examining Hox11 compound mutants 
(animals in which only one of the four paralogs is functional). Hox11 compound mutants 
		 xii	
develop normally, but skeletal growth defects begin to manifest at postnatal stages and 
adults are not able to execute proper fracture injury repair. However, results from these 
studies are complicated by the fact that three of the four Hox11 alleles are absent during 
skeletal development, making it challenging to distinguish between embryonic and 
postnatal roles. Using a novel Hoxd11 conditional allele to delete Hox function in a 
temporally and spatially regulated manner, I provide evidence that conditional loss of 
Hox11 function in the adult skeleton results in the progressive replacement of normal 
lamellar bone with an abnormal woven bone-like matrix with highly disorganized collagen 
fibers. Lineage analyses of the Hox-expressing cells demonstrate that while the stem cell 
population is maintained, osteoblast differentiation is perturbed and osteocytes embedded 
in the abnormal matrix display abnormal morphology as well as differentiation defects. 
Collectively, this research provides strong genetic and functional evidence for a continued 
role for Hox genes in the adult skeleton by regulating the differentiation of regional Hox-
expressing skeletal stem cells.  
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CHAPTER I 
Introduction 
Hox genes are patterning factors of the developing embryo 
 The Hox genes are a family of homeo-domain containing transcription factors that 
are best known for their role in providing axial positional information along the antero-
posterior (AP) axis, from the hindbrain down to the tail end of a developing embryo. Hox 
genes are highly conserved across species and the cluster organization has also been 
conserved throughout evolution1. Tandem duplication within the cluster followed by 
multiple gene duplication events that occurred during evolution ultimately led to 
mammalians having a total of 39 Hox genes. These genes are divided among four 
chromosomal clusters (Hox A-D) and further sub-divided into 13 paralogous groups 
defined by sequence similarity and position within the cluster2 (Figure 1.1). The paralogous 
groups are additionally clustered in anterior (Hox1-4), central (Hox 5-8), and posterior 
(Hox9-13) classes, mirroring their domains of expression and action, but also correlating 
with their sequence conservation in the homeodomain (HD).  
Hox genes were first discovered in fruit flies, Drosophila melanogaster, as two 
gene clusters: the Antennapedia (ANT-C) and Bithorax (BX-C) complexes3–5.  Genetic 
studies in Drosophila melanogaster demonstrated that Hox genes play a key role in 
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assigning distinct morphological identities to each body segment6. Pioneering work by E.B. 
Lewis demonstrated that mutations to one end of the BX-C complex resulted in abnormal 
morphology of anterior structures while mutations to the other end of the BX-C complex 
affected posterior structures of larvae3. Molecular cloning of the BX-C complex and 
subsequent expression studies revealed that Hox genes are expressed in a region-specific 
manner along the head-to-tail axis7,8. Results from these studies also unveiled that 
  
 
Figure 1.1. The Hox complex and its regional expression pattern along the AP and 
PD axis. A cartoon schematic of the Hox clusters in Drosophila and mammals. Hox genes 
that belong to the same paralogous group are color coded and the gradient scale along the 
AP and PD axis represent the nested, region-specific expression pattern of the paralogous 
groups along those axes (Figure from Rux, 2016 9). 
 
the physiological order of the Hox gene cluster along the chromosome closely coincides 
with their expression pattern along the head-to-tail axis, referred to as spatial collinearity7,8. 
This collinear expression of Hox genes is suggested to be regulated by the combination of 
distance, enhancer tropism, and competition for promoters upstream of the clusters that is 
refined primarily through a sequence-specific mechanism assisting in establishing a 
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preferential interaction10. During early stages of development, Hox genes are kept globally 
silent and then progressively become activated from the anterior to posterior end of the 
embryo11. As development progresses, Hox genes establish an expression pattern along the 
anteroposterior (AP) axis with an anterior limit creating some overlapping expression 
between Hox genes that are adjacent to each other12–15. As a result, each region along the 
AP axis expresses a unique combination of Hox genes referred to as “Hox code” which 
correlates with changes of the vertebral morphology12–15. Therefore, the skeletal 
organization and morphology is regulated by the genomic topography of Hox genes16,17. 
Hox genes organize the correct skeletal morphology in the axial and limb skeleton 
axes 
Coinciding with their region-specific expression pattern along the AP axis, Hox 
genes exhibit regionally restricted functions as well. Mutations to a particular paralogous 
group of Hox genes specifically affect the region those genes are expressed in. The high 
sequence similarity among Hox genes within the same paralogous group results in 
functional redundancy18–21. Mutations in a single Hox paralog generally leads to a mild or 
absence of phenotype. Therefore, in order for a discernable phenotype to manifest, multiple 
or all members from a paralog need to be mutated18,19,28–33,20–27. Loss-of-function (LOF) 
mutations of Hox genes result in what is classically referred to as anterior homeotic 
transformation. This is when the body segment where a particular paralogous group is 
expressed in is abnormally converted into the next most anterior segment3,18–20,30. For 
example, Hox10 is expressed within the lumbar region of the axial skeleton. Upon loss-of-
function mutations to the Hox10 paralogous group, the lumbar region usually devoid of 
floating rib structures now assume the phenotype of the thoractic region with rib structures 
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protruding from the lumbar vertebrae20 (Fig 1.2, far-left panel). Similarly, the loss of Hox11 
paralogs expressed in the sacral region, leads to vertebrae that display the same 
morphological characteristics of those in the lumbar region20 (Fig 1.2, far-right panel).  
 
Figure 1.2. Hox gene loss-of-function lead to homeotic transformation of axial skeletal 
morphology. (A) LOF mutation in the Hox10 paralogous group results in the 
transformation of the lumbar vertebrae to adopt the thoractic region phenotype identifiable 
by the floating rib structures (far left panel). Hox11 LOF leads to the sacral vertebrae to 
assume lumbar phenotype (far right panel). T13 indicates last rib structure within the 
thoractic region. (Figure adapted from Wellik, 200320).  
 
 
In addition to their role in axial skeleton development, the posterior Hox genes 
(Hox9 through Hox13) were co-opted to pattern the proximodistal (PD) axis of the 
appendicular limb skeleton. The vertebrate limb skeleton is subdivided into three regions 
along the PD axis; stylopod (humerus and femur), zeugopod (radius/unla and tibia/fibula), 
and autopod (digits of the forelimb and hindlimb)20,25–27 (Fig 1.3A). In the early limb bud, 
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the 5’ Hox genes are progressively expressed in distally-restricted but overlapping 
domains34–37. As the cartilage anlage for the limb skeleton elements appears, the expression 
domains of the Hox paralogs resolve such that Hox9 and Hox10 genes are primarily 
restricted to the stylopod, Hox11 genes to the zeugopod, and the Hox13 genes to the 
autopod20,25–27 (Fig 1.3A). Of note, the posterior HoxA and HoxD clusters are expressed in 
both the forelimb and hindlimb, whereas the HoxC cluster is additionally  
 
Figure 1.3. Posterior Hox genes display nested expression pattern along PD axis and 
mutations lead to region-specific defects in skeletal morphology. (A) Similar to the 
axial skeleton, the posterior Hox genes are expressed regionally along the PD axis of the 
vertebrate limb. (B) Loss-of-function mutations to posterior Hox genes within the limb lead 
to regional malformation of the appendicular skeleton. Hox10 mutants (Hoxa10-/-;Hoxc10-
/-;Hoxd10-/-) exhibit stylopod-specific malformation, Hox11 mutants (Hoxa11-/-;Hoxc11-/-; 
Hoxd11-/-) have zeugopod-specific defects, and Hox13 mutants (Hoxa13-/-; Hoxd13-/-) 
show agenesis of the autopod (Figure adapted from Wellik and Capecchi, 2003 20 and 
Fromental-Ramain et al., 1996 26).  
 
 
expressed in the hindlimb20,25,38. Similar to the axial skeleton, specific loss-of-function 
mutations to particular Hox paralogs lead to severe defects in skeletal morphology. 
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However, unlike the axial skeleton where loss of Hox function results in homeotic 
transformation of vertebral morphology, in the limb skeleton, Hox mutants display near- 
complete regional agenesis of the skeleton. For example, Hox11 triple mutants (Hoxa11-/-; 
Hoxd11-/-;Hoxc11-/-) exhibit a severe malformation of the zeugopod skeleton while the 
stylopod and autopod region mostly develop normally20,25 (Fig 1.3B). Similar regional 
defects in patterning are observed in Hox9 or Hox10 paralog mutants, and a complete loss 
of the autopod region is observed in Hox13 null mutants26,27 (Fig 1.3B).  
Hox gene function is required in early limb formation as the loss of all paralogs in 
the Hox9 group leads to the loss of Shh expression in the ZPA resulting in severe 
malformation of posterior skeletal elements39. Additionally, the Hox5 paralogous groups is 
necessary for proper anterior forelimb development as the loss of all three Hox5 genes 
result in anterior forelimb skeletal defects attributed to the de-repression of Shh 
expression40. Large deletions of the entire HoxA and HoxD clusters lead to truncation of 
the skeletal elements as well as abnormality in the specification of the correct number of 
skeletal anlages in the developing limb41. Taken together, the requirement for Hox activity 
in the proper formation and development of the appendicular skeleton is indisputable. 
However, despite ample evidence establishing the importance of Hox genes in skeletal 
patterning, there is a lack of understanding regarding the specific cellular and molecular 
mechanisms of Hox gene function. 
 
Limb skeletal development and adult bone maintenance 
Mesenchymal condensations that preconfigure the limb skeletal elements initiate 
formation in a proximal to distal fashion beginning at E10.5 in the forelimb. These pre-
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chondrogenic mesenchymal cells are derived from the lateral plate mesoderm and are first 
observed as morphologically dense, compacted groups of mesenchymal cells within the 
limb bud42. The earliest marker of pre-chondrogenic cells is the transcription factor, 
Sox943,44. Sox9-expressing cells are found scattered in the limb bud mesenchyme prior to 
condensation. These chondrogenic precursors subsequently aggregate in a proximal 
(stylopod, ~E10.5) to distal (autopod, ~E11.5) fashion to form the cartilage anlage that will 
become the skeletal elements of the limb43–46.  
 Subsequent longitudinal bone growth is fueled by the regulated proliferation and 
differentiation of chondrocytes at the distal ends of the bone. Chondrocytes within the 
growth plate are organized into distinct cellular zones with specific proliferative and 
maturity characteristics. The reserve zone, at the distal-most end of the bone, contains slow 
dividing chondrocyte progenitors, which give rise to all growth plate chondrocytes47. 
Chondrocytes in the proliferative zone are oriented into columns of cells, parallel to the 
long axis of the bone, and undergo significant proliferation to increase the number of cells 
within the growth plate48. The proliferative zone is characterized by the expression of a 
type II collagen and other cartilaginous matrix proteins such as aggrecan. At the central 
metaphyseal side of each growth plate, the hypertrophic zone is observed. Chondrocytes 
exit the cell cycle undergo hypertrophy, and transition into secreting a type X collagen 
matrix49. The hypertrophic transition zone provides the bulk of the longitudinal expansion 
of the bone50.  
 Concomitant to condensation of the pre-chondrogenic skeletal mesenchyme, a 
dense connective tissue layer forms surrounding the skeletal anlage termed the 
perichondrium. It has been suggested that the perichondrium functions to constrain the 
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radial growth and promote longitudinal growth of the developing skeletal anlage51. The 
perichondrium, and later periosteum, additional serves as a primary site of osteogenesis in 
the central bone shaft region. Osteogenesis initiates at E13.5 in the mouse, and it can be 
visualized at its earliest stages by expression of the osteogenic markers Runx2 and Osterix 
(Osx). Osteoblasts are first observed at E14.5 at the medial aspect of the anlage46. Starting 
around E14.5, Osx-expressing pre-osteoblasts enter the bone marrow space concurrent 
with vascular invasion into the medial region of the developing bone, which is mostly made 
up of hypertrophic chondrocytes52. Osteoclasts erode the hypertrophic matrix and allow 
invasion of endothelial cells into the cartilage53,54. Osteoblasts and other stromal 
populations invade the developing bone marrow space concurrent with the vasculature and 
begin depositing bony matrix that make up the primary ossification center52.  
 During rapid bone development and growth that occurs during embryogenesis and 
early postnatal growth, the skeleton is primarily composed of woven bone. Woven bone is 
characterized as a bony matrix composed of haphazardly organized collagen fibers. 
Through unclear mechanisms, this woven bone is eventually remodeled into mature 
lamellar bone that contain collagen fibers arranged in tightly organized parallel sheets or 
layers that makes up the adult bone55. Once skeletal maturity is achieved and bone growth 
has largely ceased, the bone tissue maintains its integrity and responds to functional 
demands by continuously turning over through a process termed bone remodeling56–58.  
Bone remodeling involves the removal of the old mineralized matrix by osteoclasts 
followed by the formation of new bony matrix by osteoblasts that is subsequently 
mineralized.  The resorption and formation of bone during bone remodeling are tightly 
coupled to maintain a normal bone mass. Initiation of bone remodeling begins with the 
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recruitment of hematopoietic progenitors and their differentiation into osteoclasts, induced 
by osteoblast lineage cells that express receptor activator of nuclear factor-kB ligand 
(RANKL) and macrophage-colony stimulating factor (M-CSF)59,60. Multiple cells fuse and 
further mature to produce a functional multi-nucleated osteoclast. Osteoclasts create a tight 
seal on the bone surface and release protons and proteolytic enzymes into the resorption 
compartment dissolving minerals and degrade bone matrix proteins, respectively58,61. The 
release of growth factors that were embedded in the bone matrix (e.g. TGF-b, IGFs, VEGF, 
PDGF etc. ), soluble signals, and membrane-bound proteins (e.g. ephrins, semaphorins 
etc.) all work in concert to then recruit osteoblast precursors to the resorption site. The 
recruited osteoblasts differentiate and mature to deposit new bone matrix that is eventually 
mineralized60,62. Terminally differentiated osteoblasts become embedded in the matrix they 
secrete and eventually become entrapped in the mineralized matrix becoming osteocytes. 
Osteocytes possess long dendritic processes that are enclosed by canalicular walls, forming 
a network termed the lacuna-canalicular network that connect neighboring osteocytes as 
well as bone surface cells including osteoblasts and osteoclasts63,64. This connection 
between cells play a critical role in bone homoestasis65.  
Considering Hox genes beyond embryogenesis 
Detailed analyses of Hox genes have mostly been restricted to embryonic 
development and largely unexplored at later stages. However, there is growing evidence 
for their expression extending beyond embryonic development into postnatal and adult 
stages as well as implications for their continued function. Expression profiles generated 
from multiple adult human organs show that the expression of Hox genes are maintained, 
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reflecting the regional expression pattern established during embryonic development66. 
Similarly, using human epidermal fibroblasts, it was shown that site-specific Hox 
expression was maintained in a cell-autonomous manner67. Cells isolated from various 
organs and anatomical sites also revealed characteristic Hox expression fingerprints highly 
specific for their anatomical origin68. Interestingly, expression of specific Hox paralogous 
groups could be used to distinguish between bone marrow-derived mesenchymal stem cells 
and cord blood-derived mesenchymal stem cells suggesting that distinct Hox paralog 
expression could be used to identify different cell populations69.  
Deregulation of Hox gene expression has been widely implicated as the driving force 
in tumorigenesis70. Upregulation or downregulation of Hox genes has been recognized to 
contribute to all aspects of cancer initiation and progression that include angiogenesis, 
autophagy, differentiation, apoptosis, proliferation, invasion and metastasis, and 
metabolism. HOXA9 has been found to be overexpressed in leukemia and is considered to 
be an initiating factor of leukemogenesis by epigenetic reprogramming of hematopoietic 
cells71,72. A mutation that affects the auto-regulatory enhancer of the HOXD4 gene leading 
to reduced transcriptional activity has been associated with a higher risk of acute 
lymphoblastic leukemia (ALL)73. Missense mutations in HOXB13 have been correlated 
with increased prostate cancer susceptibility and an elevated risk of leukemia, bladder, 
breast, and kidney cancers74–77. In Ewing’s sarcoma, an abnormal upregulation of the 
posterior HOXD paralogs is observed78,79. As the EWS-FLI1 fusion protein—a hallmark 
of Ewing’s sarcoma—recruits epigenetic regulators to reprogram the epigenome, studies 
have concluded that the aberrant expression of HOX genes maintains and facilitates the 
progression of this cancer78. Not only are deregulated HOX expression implicated in 
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tumorigenesis but were also found to have tumor-suppressive roles in distinct contexts. The 
p53 gene protects cells from malignant transformation and HOXA5 was found to 
transcriptionally regulate p53 in breast cancer tumor cells by directly binding to the p53 
promoter80–83. Additionally, HOXA5 expression in breast cancer cells induced apoptosis 
mediated by caspase 2 and 884. Together, whether HOX genes are associated with the 
progression or suppression of malignancies, it is evident that the transcription of HOX 
genes continue to be actively regulated in these malignancies after birth. 
Coinciding with the continued expression of Hox genes in various organs and tissues, 
their continuous function after embryogenesis have been implicated. The loss of any 
complete set of Hox paralogous group results in embryonic lethality. Therefore, much of 
the insight in the continuing function of Hox genes have been gained by examining 
compound mutants that have only one functional paralog allele. The zeugopod forelimb of 
Hox11 compound mutants develop normally but start to show phenotypes at postnatal 
stages with an overall shortened ulna and bowing of the radius85. At adult stages, these 
compound mutants are unable to execute normal fracture repair86,87. At the early stages of 
fracture repair, compound mutants are incapable of generating cartilage within the fracture 
callus leading to an incomplete bridging of the fracture gap87. This gap is never resolved 
in the Hox11 compound mutants even out to 12 weeks-post-fracture and the skeleton fails 
to resume its original structure86. Together, these findings are consistent with the possibility 
of a continuing function of Hox genes that extend beyond their embryonic role.  
In order to further understand the cellular mechanisms of Hox function in the adult 
skeleton, efforts were devoted to establishing the identity of adult Hoxa11eGFP-
expressing cells during bone homeostasis and fracture repair. Importantly, the expression 
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of Hox11 remains regionally-restricted to the zeugopod skeleton through postnatal and 
adult stages (Figure 1.4 and 86). During fracture repair, its expression increases in response 
to injury and is highly expressed in cells within the fracture callus86,87. Extensive co-
expression analyses revealed that during both fracture repair as well as normal, un-injured 
adult bone, Hoxa11eGFP  is not expressed in mature osteoblasts, cartilage cells, fat cells, 
neurons, blood cells, or blood vessels86. Flow cytometry analyses demonstrated that 
Hox11-expressing cells are restricted to the non-hematopoietic, non-endothelial stromal 
compartment of the bone marrow and perichondrium86. Cell surface marker analyses and 
genetic lineage-tracing models determined that Hox11-expressing cells are a population of 
mesenchymal stem cells (MSCs) that co-express PDGFRa/CD51 and Leptin-receptor 
(LepR)86.  
 
 
Figure 1.4. Hoxa11eGFP expression in the developing limb bud and maintenance of 
its expression beyond embryogenesis. Expression of Hoxa11eGFP is observed by the 
cells expressing GFP (green) in real-time during limb bud development while the 
condensing skeletal anlage is observed by an early chondrocyte marker, Sox9 (red). Hox11 
expression initiates at ~E9.5 with it becoming restricted to the zeugopod region by E11.5 
and continues through postnatal and adult stages. Bottom panel shows Hoxa11eGFP 
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expression (blue) that remains restricted to the zeugopod region 2-weeks after birth (Figure 
adapted from Swinehart et al., 2013 88 and Rux et al., 2016 86).  
While there is mounting evidence that imply a continuing role for Hox genes at adult 
stages, there are several caveats that must be taken into consideration when assessing these 
results. The interpretation of the phenotypes of compound mutants are complicated by the 
fact that three alleles are absent throughout embryonic development as well as postnatal 
and adult stages. Therefore, it is challenging to separate developmental defects that 
manifest later in life from the adult stage functions. Hox expression continues in multiple 
adult cell types, however it remains to be shown whether this expression confers any 
significant functional meaning. Further, it is difficult to establish a cause and effect 
relationship between the differential expression of Hox genes and various diseases. 
Therefore, whether Hox genes continue to function in whichever organ or tissue it is 
expressed in after birth remains an open question. 
Mesenchymal stem cells (MSCs) or skeletal stem cells 
 The existence of adult stem cells was first described by Till and McCulloch when 
they showed that cells from the bone marrow are capable of giving rise to mesenchymal 
cell types (osteoblasts, chondrocytes, and adipocytes) and maintain self-renewal89–91. 
Subsequently, Friedenstein and colleagues demonstrated that the rodent bone marrow 
contained cells capable of forming fibroblastoid colonies (CFU-F), were plastic adherent, 
gave rise to bone, and could reconstitute a hematopoietic microenvironment when 
transplanted subcutanesouly92–95. When similar cells were identified in human bone 
marrow aspirates, these cells were given the name “mesenchymal stem/stromal cells 
(MSCs)”96.  
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 The identification and characterization of MSCs were primarily fueled by the fact 
that they were in close proximity to hematopoietic stem cell (HSC) niches associated with 
blood vessels in the bone marrow and were regarded as critical regulators of the HSC niche. 
Bone marrow stromal cells adjacent to blood vessels express crucial HSC niche factors 
such as C-X-C motif chemokine 12 (CXCL-12), stem cell factor (SCF), Angiopoietin-1 
(Ang-1), interleukin-7, vascular cell adhesion molecule-1 (VCAM-1) among others97,98. 
Manipulation of these perivascular MSCs by genetic ablation led to disruption of 
hematopoietic lineages and HSC maintenance. For example, the ablation of Nestin-GFP+ 
cells that primarily localize around bone marrow blood vessels resulted in a significant 
reduction in hematopoietic stem/progenitor cells99. Genetic ablation of CXCL12-abundant 
reticular (CAR) perisinusoidal cells led to premature differentiation of hematopoietic 
myeloid cells100,101. Additionally, removing fibroblast activation protein (FAP)-expressing 
bone marrow stromal cells resulted in bone marrow hypocellularity and anemia102. The 
deletion of LepR-expressing MSCs from the bone marrow compartment also led to the 
depletion of  hematopoietic stem/progenitor cells103,104. Together with other findings, these 
results indicated that MSCs are a crucial constituent of the HSC niche. 
 Due to the close proximity and intimate regulation, studies ensued to dissect the 
lineage relationship between HSCs and MSCs. Results determined that the two population 
of stem cells are derived from individual, distinct lineages105. Further, the discovery of cell 
surface markers for the specific identification of MSCs was demonstrated. At this point, 
the primary focus of MSCs as constituents of the HSC niche shifted. MSCs began to be 
recognized as a potential skeletal stem cell population that provides a reservoir of stem 
cells continuously supplying appropriate skeletal lineage cells.  Plastic adherence, 
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expression of specific cell surface antigen, and multipotent differentiation potential became 
the official defining characteristics of MSCs106. Additionally, MSCs are required to exhibit 
self-renewal in order to be characterized as a stem cell107.  
Genetic mouse models have proven extremely useful in characterizing MSC 
subpopulations in vivo. The Nestin-GFP transgenic mouse model was the first to be 
rigorously interrogated. Nestin-GFP+ cells identified rare perivascular stromal cells99. 
These cells were shown to be capable of multi-lineage differentiation in vitro giving rise 
to osteoblasts, chondrocytes, and adipocytes. Self-renewal was demonstrated by serial 
transplantation of mesenspheres supporting the stem cell properties of this population99. 
While the discovery of the Nestin-GFP-expressing cells provided valuable insight in MSC 
biology, the intracellular location of the Nestin protein precluded prospective live cell 
isolation for additional characterization. In a follow-up study, Pinho et al. identified the 
cell surface markers, PDGFRa/CD51 (integrinaV), to encompass a large fraction of the 
Nestin-GFP-expressing cells108. The PDGFRa+/CD51+ subset of Nestin-expressing cells 
further enriched for MSCs as they contained almost all CFU-F and mesensphere-forming 
activity and displayed robust tri-lineage differentiation (osteoblast, chondrocyte, and 
adipocyte) in vitro108.  In vivo confirmation of the multi-lineage capacity of the Nestin-
expressing cells was further interrogated by the use of an inducible Nestin-CreER. 
Postnatal stage induction of recombination followed by lineage-tracing of the Nestin 
lineage revealed that these progenitor cells gave rise to osteoblasts and chondrocytes, but 
not adipocytes in vivo109. Intriguingly, neither adult nor postnatal induction led to 
adipocytes marked by the Nestin-CreER lineage. Discrepancies between in vitro lineage 
contribution and in vivo multi-lineage potential demonstrated that in vitro assays do not 
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faithfully illustrate the differentiation capacity of MSCs in vivo highlighting the importance 
of careful examination of MSCs in their endogenous environment. The absence of Nestin 
-CreER labeled adipocytes additionally suggested the potential existence of other 
populations of MSCs that contribute to distinct skeletal cell types99,109.  
Additional progenitor populations identified include Myxovirus resistance-1(Mx1)-
Cre lineage labeled cells that were strictly comprised of osteoblasts with little to no 
contribution to chondrocytes or adipocytes in vivo110. Gremlin-1 (Grem1)-CreERT 
induction at both postnatal and adult stages led to lineage-labeled chondrocytes and some 
contribution to the osteolineage111. A mouse model where in vivo adipocyte contribution 
was observed was in the Leptin Receptor-Cre mouse model. This genetic marker identified 
the broadest MSC population containing the majority of CFU-F activity of bone marrow 
cells in the adult112. Fate-mapping of the LepR-Cre cells revealed that contribution to the 
adult bone begins at 15-weeks of age and that most of the osteoblasts in the adult bone 
were LepR-lineage labeled112. Adipocytes were also found to be lineage labeled with LepR. 
However LepR-lineage marked chondrocytes were only found during fracture repair, but 
not homeostasis112. An important fact to consider is that this model harbor a ubiquitous Cre 
allele with no temporal control. Therefore, it cannot be excluded that LepR expression 
initiated in the differentiated osteoblasts and adipocytes to subsequently mark them. Thus, 
the lineage relationship between LepR-expressing MSCs and mature osteoblasts or 
adipocytes cannot be determined. Additionally, while expression of LepR initiates during 
late embryogenesis (~E17.5), LepR-lineage-labeled cell contribution to bone is not 
observed until 15 weeks of age112. This indicates that a distinct population of MSCs must 
contribute to the development and growth of the skeleton.  
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MSC populations that support early skeletal development and growth were 
demonstrated by the Prx1-Cre model that labels the entire limb bud mesenchyme derived 
from the lateral plate mesoderm113. Embryonic and postnatal induction of Osx-CreERT and 
Osx-CreERT2 models demonstrated a robust contribution to early skeletal development 
and growth114,115. These lineage-labeled cells exhibited multi-lineage potential as well. 
Interestingly, embryonic induction of the Osx-CreERT2 model demonstrated the existence 
of a transient source of skeletal progenitors. Virtually no embryonically induced lineage-
labeled cells were found in the adult bone; however, postnatal induction of the same model 
exhibited a life-long contribution to bone115. This led to the notion of the ‘waves of 
progenitors’ where distinct, age-dependent MSC populations arise to separately support 
the development, growth, and maintenance of bone. It is important to note that many of the 
genes used in these mouse models are known to be expressed in mature cell types. Osterix 
is expressed in osteoblasts, nestin is expressed in endothelial cells, and LepR is expressed 
in neurons116–118. Therefore, this raises the possibility of these models marking downstream 
progenitor populations rather than a true skeletal stem cell.  
As more subsets of MSCs were identified in the skeleton, the heterogeneous nature 
of MSCs was increasingly evident. Nestin-CreER lineage-labels two subsets: one found 
closely associated with endothelial cells, co-expressing CD31, predominantly found in the 
perichondrium while the other does not express CD31 and is found to encompass the early 
osteoblast lineage during limb skeletal development109. The heterogenous nature of MSCs 
was further reinforced by the Nestin-GFP-expressing population as one subset expresses 
high levels of Nestin-GFP (Nestin-GFPhigh)  that mainly localized around arterioles and the 
other expresses low levels of Nestin-GFP (Nestin-GFPlow) primarily found near 
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sinusoids119. Bone marrow stromal cells marked by Leptin-receptor (LepR)-Cre only label 
a subset of the Nestin-GFP-expressing cells while virtually all (>95%) LepR-lineage 
labeled cells express PDGFRa, CD51, PDGFRb, and a high proportion (68%) expresses 
CD105112. PDGFRa+/Sca1+ was one of the earlier MSC subsets to be isolated by cell 
surface markers120 and minimal overlap was observed between Sca1+ and LepR+ cells. 
Mouse skeletal stem cells (mSSCs) that are CD51+/CD200+ was demonstrated to give rise 
to multiple downstream progenitor populations ex vivo in ectopic transplantation models 
into the kidney capsule121. During development, mSSCs and PDGFRa+/Sca1+ arise as 
mutually distinct populations encompassed within the PDGFRa+/CD51+ population122. 
Moreover, based on expression of CD73 and CD90 four sub-populations within 
PDGFRa+/Sca1+ was identified with distinct differentiation potentials in vitro122.  
In addition to the heterogeneity identified by cell surface marker expression, the 
existence of regionally distinct MSCs are beginning to emerge adding another layer of 
complexity. A Cathepsin K-Cre (CatK-Cre) model was shown to label periosteal stem cells 
that are largely excluded from the mesenchymal cells within the bone marrow or endosteal 
compartment123. Coinciding with this finding, the behavior of stem/progenitor cells from 
the periosteum were found to be distinct from that of bone marrow MSCs during fracture 
repair. Periosteal stem/progenitor cells were more migratory and contributed to the fracture 
callus more extensively compared to bone marrow mesenchymal cells124. The 
transcriptional profile between the periosteal and bone marrow stem/progenitor cells were 
also found to be distinct supporting the distinct nature of the MSC population separated by 
location124. Relatively recently, our laboratory has shown that Hoxa11eGFP expression is 
exclusive to a population of progenitor-enriched adult MSCs86. As mentioned above, Hox 
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expression is regionally restricted in the skeleton throughout life. Intriguingly, the Hox 
signature established during embryogenesis is retained strictly within MSCs (defined by 
LepR-lineage labeled cells) in bones isolated from various axial levels86. Consistent with 
these results, another group reported that Hox gene expression status in periosteal 
stem/progenitor cells from distinct anatomical sites were found to best define the 
differences found in their transcriptome125. Taken together, it is becoming evident that the 
skeleton is comprised of many different populations of MSCs that display distinct 
contributions to skeletal development, growth, maintenance, and injury repair. However, 
this raises an important question of whether there is a common origin to all of these sub-
populations. Moreover, the question of whether a true stem cell exists within the skeleton 
is still unclear.  
Summary of thesis work 
 The overarching goal of the work presented in this thesis is to understand the 
mechanism of Hox gene function in the adult mammalian skeleton. The forelimb zeugopod 
skeleton where Hox11 is expressed was used as a model to gain insight into this question. 
Specifically, understanding the cellular nature of Hox-expressing cells within the skeleton, 
assessing the stem/progenitor capacity of Hox11-expressing cells in vivo, and to determine 
a continued function for Hox genes in the adult skeleton are presented in this thesis.  
 Previous work from our laboratory defined Hox11-expressing adult cells as 
mesenchymal stem cells (MSCs) characterized by co-expression of published MSC cell 
surface markers and in vitro multi-lineage potential86. However, whether the Hox11-
expressing cells are capable of stem/progenitor activity in vivo was not clear. To address 
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this question, an inducible Hoxa11-CreERT2 allele was generated (by Kyriel Pineault) in 
order to track the Hox11-expressing cells in vivo and examine their behavior throughout 
skeletal growth, development, and maintenance. Here, I show that Hox11-expressing cells 
give rise to all skeletal lineages including osteoblasts, chondrocytes, adipocytes, and most 
critically exhibit self-renewal throughout life. Additional insight into lineage relationships 
among other published sub-populations that exist within the skeleton was also revealed in 
this study. I performed all the flow cytometry experiments related to this work and my 
work demonstrates a life-long population of skeletal stem cells established during 
embryogenesis.  
 As mentioned previously, the requirement for Hox genes after the skeleton has been 
established has been largely unknown.  As the stage-specific functions of Hox genes is 
difficult to separate in results from Hox compound mutants, a Hoxd11 conditional allele 
was generated. This allows for the deletion of Hox11 function at any stage while 
maintaining normal development and growth until deletion. In this work I show that the 
conditional loss of Hox11 function at adult stages lead to a progressive replacement of 
normal lamellar bone with an abnormal woven bone-like matrix containing haphazardly 
organized collagen fibers. Lineage-analysis determined that while osteoblast 
differentiation is initiated, subsequent maturation does not occur, and downstream 
osteocytes are affected as well exhibiting differentiation and morphological defects. 
Critically, the function of Hox11 remains regionally restricted as the humerus from the 
conditional mutants do not display defects. Collectively, this work demonstrates a 
continuing function for Hox genes beyond embryonic development by regulating the 
differentiation of regional Hox-expressing skeletal stem cells.  
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CHAPTER II 
Hox11 Expressing Regional Skeletal Stem Cells Are 
Progenitors for Osteoblasts, Chondrocytes and Adipocytes 
Throughout Life 
Summary 
Multipotent mesenchymal stromal cells (MSCs) are required for skeletal formation, 
maintenance, and repair throughout life; however, current models posit that postnatally 
arising long-lived adult MSCs replace transient embryonic progenitor populations. We 
previously reported exclusive expression and function of the embryonic patterning 
transcription factor, Hoxa11, in adult skeletal progenitor-enriched MSCs. Here, using a 
newly generated Hoxa11-CreERT2 lineage-tracing system, we show Hoxa11-lineage 
marked cells give rise to all skeletal lineages throughout the life of the animal and persist 
as MSCs. Hoxa11 lineage-positive cells give rise to previously described progenitor-
enriched MSC populations marked by LepR-Cre and Osx-CreER, placing them upstream 
of these populations.  Our studies establish that Hox-expressing cells are skeletal stem cells 
that arise from the earliest stages of skeletal development and self-renew throughout the 
life of the animal.   
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Introduction 
 Hox genes play well-established roles in patterning the embryonic skeleton. Hox1 
through Hox13 paralogs are expressed and function regionally along the anterior-posterior 
axis of the axial skeleton, with the Hox9-Hox13 paralogs co-opted to also pattern along the 
proximal to distal axis of the appendicular skeleton. The Hox11 paralogs, Hoxa11, Hoxc11 
and Hoxd11, pattern the sacral region of the spine and the zeugopod region of the limb 
(radius/ulna and tibia/fibula)20. Loss of Hoxa11 and Hoxd11 function during development 
results in dramatic mis-patterning of the forelimb zeugopod skeleton25. In addition to 
complete loss-of-function phenotypes observed during development, compound mutants 
exhibit defects in skeletal growth during postnatal stages and in adult fracture repair85–87.  
 Despite clear genetic evidence for Hox function in the skeleton, Hox expression is 
excluded from all mature skeletal cell types at all stages, including chondrocytes and 
osteoblasts20,86,88. Embryonically, Hox11 expression is observed in the developing 
zeugopod perichondrium immediately adjacent to Sox9-positive chondrocytes and, as the 
skeleton begins to ossify, expression continues in the periosteum, adjacent to Osterix-
positive pre-osteoblasts88. At postnatal and adult stages, Hox11-expressing cells remain in 
the outer periosteal stroma adjacent to the osteoblast layer, and are additionally observed 
in the bone marrow and along the endosteal (inner) bone surface20,86. Adult Hox11-
expressing stromal cells from the bone marrow and periosteum are exclusively identified 
by antibodies that mark progenitor-enriched mesenchymal stem/stromal cell (MSC) 
populations including PDGFRα/CD51 and Leptin-Receptor (LepR) as well as by Leptin 
Receptor-Cre (LepR-Cre)86,108,112. In vitro, Hox11 mutant MSCs are unable to differentiate 
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into chondrogenic and osteogenic lineages, supporting a function for Hox11 genes in this 
population86.  
 Several previous lineage labeling models have reported labeling of progenitor-
enriched, bone marrow MSC populations, however, with the exception of Prx1-Cre, which 
labels the entire limb lateral plate mesoderm126, inducible lineage reporters only mark only 
a minor proportion of a multipotent, self-renewing population from postnatal stages, and 
only when induced at postnatal stages. These models include Osterix-CreER (Osx-CreER), 
Sox9-CreER, Aggrecan-CreER, PthrP-CreER, and Gremlin1-CreER111,115,127,128. The 
LepR-Cre lineage reporter, while not inducible, eventually marks the majority of the 
progenitor-enriched MSCs in the adult bone marrow112,115. Of note, this model does not 
give display robust contribution to osteoblasts until 5-6 months of age112,115. Recent 
evidence showed embryonic and postnatal Gli1-CreER lineage marked cells are multi-
potent and give rise to LepR-positive bone marrow MSCs in the adult129. However, the 
pattern of contribution to the skeleton differs significantly based on the induction time 
points, indicating that this lineage-marked population is not equivalent at embryonic and 
postnatal stages.  
Previous work has genetically established the importance of Hox11 genes in 
embryonic skeletal development, postnatal growth, and adult fracture repair85–87. 
Considering the continuity in Hoxa11eGFP expression in the zeugopod skeleton 
throughout life and the recent identification of adult, Hox11-expressing cells as skeletal 
MSCs, we sought to test the progenitor capacity of the Hox11-expressing population 
throughout the life of the animal. To do this, we generated a Hoxa11-CreERT2 lineage-
tracing allele and we find that Hoxa11-lineage marked cells continuously give rise to all 
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the skeletal mesenchymal lineages (cartilage, bone, and fat) during embryonic 
development, postnatal growth, at homeostasis and in response to injury. Even when 
lineage labeling is initiated at embryonic stages, Hoxa11-lineage marked stromal cells 
arising from this lineage co-express MSC markers PDGFRα/CD51 and LepR. In contrast 
to other reported embryonically-induced progenitor populations, the Hoxa11-lineage is 
maintained as progenitor-enriched MSCs in adult bone marrow and demonstrate strong 
lineage labeling of all skeletal lineages through at least one year of age. Further, Hoxa11 
lineage-marked MSCs also express Hoxa11eGFP at all stages examined. These results 
provide strong evidence for the in vivo self-renewal of this MSC population.  
 To understand the lineage relationships between Hox11-expressing cells and other 
genetically marked progenitor/MSC populations, we compared Hoxa11eGFP expression 
to cells genetically lineage labeled by LepR-Cre and Osx-CreER112,115,127. Herein, we show 
that Hox11-expressing cells serve as upstream progenitors that give rise to cells marked by 
these other genetic models. Taken together, these data support Hox-expressing skeletal, 
stromal cells as a bona fide skeletal stem cell population and demonstrates the presence of 
a specific, lineage-continuous skeletal stem cell population from embryonic stages 
throughout life. 
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Results 
Hox11 expression defines a continuous progenitor population  
Hox11 expression is regionally-restricted in the embryonic zeugopod limb 
(radius/ulna and tibia/fibula) and is observed in cells of the perichondrium surrounding the 
chondrocyte anlage [Figure 2.1a].  As osteoblast differentiation commences, Hox11 
continues to be expressed in the outer periosteum immediately adjacent to the 
differentiating osteoblast layer [Figure 2.1b and 88]. Throughout embryonic, postnatal, and 
adult life, Hoxa11eGFP-expressing cells persist on the periosteal surface, but also become 
observed on the endosteal bone surfaces and as stromal cells within the bone marrow space 
beginning at postnatal stages [Figure 2.1c-f]. At later stages, Hoxa11eGFP expressing cells 
remain non-overlapping with osteoprogenitors on the bone surfaces [Figure 2.1g, 
arrowheads and 86]. We previously demonstrated that adult Hoxa11eGFP-expressing cells 
are exclusively identified by co-expression of PDGFRα/CD51 and of LepR, cell surface 
markers for progenitor-enriched MSCs86,108,112. Consistent with the possibility that Hox11 
expression defines skeletal mesenchymal progenitors throughout life, Hoxa11eGFP-
expressing cells are observed in several regions that have been demonstrated to contain 
skeletal progenitors including the distal growth plate, the perichondrium/periosteum, and 
the trabecular bone. [Figure 2.1h and 47,52,128,130,131]. Periostin expression was recently 
identified to mark MSCs with enriched bone-forming potential compared to bone marrow 
MSCs124. Intriguingly, Hoxa11eGFP-expressing cells in the outer periosteum are not 
positive for periostin at adolescent or adult stages, however, the more weakly-postive 
Hoxa11eGFP cells in the inner periosteal layer do overlap with periostin staining, 
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correlating the expression of both of these proteins with high progenitor activity in this 
region of the skeleton [Figure 2.1i-j]. 
 
Figure 2.1. Hoxa11eGFP expression defines a continuous stromal population. (a-f) 
Hoxa11eGFP expression in the forelimb zeugopod (radius and ulna) shown from 
embryonic to adult stages with proximal on left and distal on right in all images. 
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Hoxa11eGFP expression in radius and ulna (a-c), higher magnification images show 
cartilage marker, Sox9 at E13.5 (A, red) and osteoblast marker, Osterix at E14.5 (b, 
magenta). (d-f) mid-diaphysis radius (r) and ulna (u) (higher magnification images of mid-
diaphysis ulna, white dashed box, shown on right). (g) Hoxa11eGFP and Osterix (red) at 8 
weeks, white arrowheads identify individual Osterix positive nuclei. (h) Hoxa11eGFP 
(green) in E15.5 distal growth plate and higher magnification of perichondrium (white 
boxed region, bracket), 8 week periosteum (bracket), and P4 trabeculae. (i-j) Periosteal 
Hoxa11eGFP and Periostin (red) at 2 week (i) and 8 weeks (j). Dashed white lines mark 
periosteal boundary dotted line separates inner and outer layers. (j) Cell marked by asterisk 
magnified in inset. In all images, green: Hoxa11eGFP, grey: DAPI. Bone marrow: bm, 
periosteum: po, endosteum: endo, cortical bone: cb, perichondrium: pc. Scale bars; (a, b, 
d-f left panels, h growth plate) 200μm, (c) 500μm, (d-f right panels, h trabecular bone) 
100μm, (g, h periosteum, i-j) 50μm. 
 
We analyzed Hoxa11eGFP-expressing cells from embryonic, postnatal, and adult 
stages for co-expression of PDGFRα/CD51 and LepR by flow cytometry. At embryonic 
stages, analyses were performed on the entire skeletal anlage, while at postnatal and adult 
stages, the bone marrow and bone adherent fractions were analyzed separately. 
Hoxa11eGFP-expressing cells from embryonic stages through one year of age co-label 
with PDGFRα and CD51 in both compartments [Figure 2.2a and Supplemental Figure 1b]. 
In agreement with previous reports, LepR expression does not initiate until approximately 
newborn stages112,115. Consistent with increasing expression in stromal progenitors during 
postnatal life, co-expression of LepR in the Hoxa11eGFP-expressing cells increases during 
this time; by adult stages, the majority of Hoxa11eGFP-expressing cells are also LepR-
positive [Figure 2.2a and Supplemental Figure 2.1b]. Interestingly, LepR expression 
increases more slowly within the bone adherent compartment compared to the bone 
marrow compartment [compare Supplemental Figure 2.1b to Figure 2.2a]. While it has not 
been established whether adult MSC cell-surface markers label progenitors during 
embryogenesis, Hoxa11eGFP-expressing stromal cells maintain a constant cell surface 
signature from the stage when each marker is first expressed. Primitive postnatal 
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progenitors, coined mouse skeletal stem cells (mSSCs), are one of the earliest MSC 
populations defined by flow cytometry121. Overlap (50-60%) between Hoxa11eGFP-
expressing cells and the mSSC population is observed demonstrating that a sub-population 
of postnatal Hox-expressing stromal cells are mSSCs [Figure 2b-c]. These collective data 
provide strong support for the hypothesis that Hoxa11eGFP-expression identifies a skeletal 
MSC population from early stages. 
 
Figure 2.2. Hoxa11eGFP expressing cells co-express MSC markers throughout life. 
(a) Flow cytometry analyses of whole skeletal anlage (E12.5 [n=4], E14.5 [n=6], and P0 
[n=6]) or flushed bone marrow (P14 [n=9], 8 week [n=10], 6 month [n=4], and 1 year 
[n=3]). Gating strategy and bone surface analyses Supplemental Figure 2.1a,b. Non-
hematopoietic, non-endothelial stromal compartment (CD45-TER119-CD31-) was gated 
on PDGFRα/CD51 (top) or Leptin Receptor (LepR-Ab, bottom). Percentages reflect 
proportion of Hoxa11eGFP-positive population within double-positive gate (top) or 
bracketed region of histogram (bottom). Charcoal dots or grey histogram: total non-
endothelial stroma (NES), green dots or green histogram: Hoxa11eGFP-expressing non-
endothelial stroma (Hoxa11eGFP+). (b-c) Flow cytometry analyses of whole P3 bones. 
Gating strategy Supplemental Figure 2.1c. Non-hematopoietic, non-endothelial stromal 
compartment (CD45-TER119-CD31-) was gated for (b) Hoxa11eGFP-positive population 
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(green box) and subsequently for mouse skeletal stem cells(mSSC, αV+Tie2-Thy-6C3-
CD105-CD200+, blue box) or (c) mSSC population (blue box) and subsequently for 
Hoxa11eGFP-expression (green box). Percentages reflect proportion of cells within 
indicated gate. ‘n’ values indicate biologically independent animals for each time point. 
All data presented as mean ± standard deviation. 
 
Cas9/CRISPR generation of a Hoxa11-CreERT2 allele  
To rigorously examine the lineage potential of Hox11-expressing cells in vivo, we 
generated a tamoxifen-inducible Cre knock-in at the Hoxa11 locus using Cas9/CRISPR 
mediated gene editing [Supplemental Figure 2.2a].  Briefly, two guide RNA sequences 
were designed to cut near the boundaries of exon 1 and a recombination plasmid was 
generated containing a tamoxifen-inducible Cre cassette (CreERT2) with the rabbit β-globin 
poly-adenylation sequence132. This recombinant template was flanked by 1.3kb of 
homology upstream and downstream of exon 1. The editing strategy resulted in 
replacement of exon 1 with CreERT2 followed by a strong stop sequence while maintaining 
the endogenous Hoxa11 surrounding sequences. Founder animals were screened by PCR 
for insertion of Cre sequence [Supplemental Figure 2.2b]. Targeting to the Hoxa11 locus 
was validated by Southern Blot analyses using 5’ and 3’ flanking probes as well as an 
internal probe for Cre [Supplemental Figure 2.2c]. Hoxa11-CreERT2 mice were crossed to 
ROSA26-LSL-tdTomato reporter mice and no tdTomato expression was observed in the 
absence of tamoxifen administration [Supplemental Figure 2.2d].  
 
Hoxa11 lineage shows life-long contribution to skeleton 
The in vivo lineage potential of Hox11-expressing cells was assessed by generating mice 
of the genotype Hoxa11CreERT2; ROSA26-LSL-tdTomato to report lineage contribution to 
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the skeleton [Figure 2.3a]. A Hoxa11eGFP real-time reporter allele was also including in 
some animals to determine if Hoxa11-lineage marked cells persist as Hox11-expressing 
MSCs133. Lineage-tracing was initiated by administering tamoxifen to pregnant dams at 
E13.5, a time point at which embryonic Hoxa11eGFP expression has become restricted to 
the stromal population surrounding the condensed zeugopod cartilage, but several days 
prior to the formation of a bone marrow cavity [Figure 2.3b and 88]. Embryonic Hoxa11-
lineage marked cells (Hoxa11E13.5) closely matched Hoxa11eGFP expression further 
confirming the integrity of the Hoxa11-CreERT2 allele [Figure 2.3b]. 24 hours following 
tamoxifen injection, the majority of lineage-marked cells are localized within the 
perichondrial/periosteal stroma surrounding the skeletal element with little to no overlap 
with Sox9-postive chondrocytes and Osx-positive osteoblasts [Figure 2.3c-d, brackets]. 
Two days after injection, at E15.5, the embryonic anlage has begun to mature, with 
cartilaginous growth plates on the distal ends and ossification initiating in the center of 
each skeletal element. Hoxa11E13.5-lineage marked cells are observed throughout the 
perichondrium/periosteum surrounding the zeugopod elements and additionally within the 
growth plate and on the bone surface [Figure 2.3e]. Significant overlap of Hoxa11E13.5-
lineage marked cells and Hoxa11eGFP-expressing cells continues to be observed, while 
the Hoxa11-lineage marked population has expanded [Figure 2.3f and Supplemental 
Figure 2.3a]. By E18.5, Hoxa11E13.5-lineage marked cells are observed throughout the 
zeugopod growth plate, within the primary spongiosa, and in the outer periosteal region 
[Supplemental Figure 2.3b-d]. Hoxa11E13.5-lineage marked cells contribute to both growth 
plate chondrocytes and osteoblasts at E18.5, demonstrating that the Hox11-expressing 
population marks multipotent skeletal progenitors that function during embryogenesis 
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[Supplemental Figure 2.3b-d]. 
Following the Hoxa11E13.5-lineage marked population after birth reveals continued 
lineage labeling throughout the periosteum, the endosteum, and within the established bone 
marrow space [Figure 2.3g and inset]. This pattern of distribution continues through adult 
stages where extensive lineage-labeling is observed [Figure 2.3h]. Consistent with the 
regional expression of Hoxa11eGFP, Hoxa11E13.5-lineage marked cells only contribute to 
the zeugopod skeleton and no lineage labeling in the stylopod (humerus) is observed at any 
stage, demonstrating that this progenitor population remains regionally restricted [Figure 
2.3h, inset]. Hoxa11E13.5-lineage marked cells continue to show remarkably strong 
contribution to the skeleton as late as one year of age [Figure 2.3i-j]. 
Lineage-labeling was then initiated at postnatal stages, a time when other genetic 
models have demonstrated contribution to long-lived stromal MSC cells. Tamoxifen was 
administered at postnatal day 3 (P3) and the contribution of Hoxa11 lineage-marked cells 
(Hoxa11P3) was examined. During the first days following tamoxifen administration, 
Hoxa11P3-lineage marked cells are observed within the perichondrium surrounding the 
distal growth plate and on the periosteal, the endosteal, and the trabecular bone surfaces 
[Figure 2.3k]. At 24 hours following tamoxifen administration, Hoxa11P3-lineage labeled 
cells are largely restricted to the periochondrium/periosteum and again show little overlap 
with Sox9-positive chondrocytes and Osx-positive osteoblasts [Figure 2.3l-m, brackets]. 
The pattern of Hoxa11P3-labeling shows clear overlap with Hoxa11eGFP expression 
[Figure 2.3n]. 
Following an 8-week chase, Hoxa11P3-lineage marked cells contribute to the 
skeleton and are observed on periosteal and endosteal bone surfaces as well as throughout 
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the bone marrow space [Figure 2.3o]. Similar to E13.5 lineage-induction, Hoxa11P3-
lineage marked cells give rise to the skeletal lineages within the zeugopod and lineage 
contribution is not observed in the stylopod at this or any stage [Figure 2.3o, inset]. 
Hoxa11P3-lineage marked cells persist and continue to contribute to the skeleton through 
one year of age [Figure 2.3p-q]. Of note, lineage induction at postnatal stages looks 
indistinguishable from embryonic induction, consistent with the Hox11-expressing 
population representing skeletal progenitors with equivalent capacity at both stages. 
 
Figure 2.3. Hoxa11-lineage contributes to the zeugopod skeleton throughout life. (a) 
Schematic of Hoxa11-CreERT2 allele. Exon 1 of Hoxa11 was replaced with CreERT2 
followed by a rabbit β-globin poly-adenylation stop sequence (see materials and methods). 
Endogenous sequence in blue, edited sequence in red, start site marked by ‘ATG’. (b-j) 
Pregnant females were given tamoxifen at E13.5 and resulting Hoxa11eGFP;Hoxa11-
CreERT2;ROSA-tdTomato animals were examined at indicated ages. Shown are complete 
limb (b, e, h), distal radius (r) and ulna (u) (f-g) or distal diaphysis region of tibia (i-j). (c) 
Expression of Hoxa11iTom and chondrocyte marker, Sox9 (green) at E14.5, dashed white 
lines demarcates anlage and bracket marks perichondrium (d) Expression of Hoxa11iTom 
and osteoblast marker, Osterix (green) at E14.5, bracket marks periosteum. (f) Co-
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expression of Hoxa11eGFP and Hoxa11iTom. (g) Inset shows Hoxa11-lineage marked 
bone marrow stromal cells (white dashed box) (k-q) P3 pups received tamoxifen and 
Hoxa11eGFP; Hoxa11-CreERT2; ROSA-tdTomato mice were examined at indicated ages. 
Shown are complete (k, o), mid-diaphysis ulna (n), or distal region of tibia (p-q). (l) Co-
expression of Hoxa11iTom and chondrocyte marker, Sox9 (green) in the growth plate at 
P4 Boxed region enlarged to right, dashed white line demarcates perichondrial border. (m) 
Co-expression of Hoxa11iTom and osteoblast marker, Osterix (green) in the periosteum 
(bracket) at P4. (b, n) Right panel shows co-expression of Hoxa11iTom with Hoxa11eGFP 
(h, o) Inset shows complete humerus. Dashed white box shown magnified to right; view 
of mid-diaphysis ulna. All images shown with distal end of bone to right. In all images, 
red: Hoxa11-lineage marked cells (Hoxa11iTom), green: Hoxa11eGFP-expressing cells 
(unless otherwise noted), grey: DAPI. Bone marrow: bm, perichondrium: pc, periosteum: 
po, endosteum: endo. Scale bars: (c, n) 100μm, (d) 50μm. All other scale bars = 200μm. 
 
Hoxa11 lineage becomes all skeletal/mesenchymal cell types 
To assess the contribution of Hoxa11-CreERT2 lineage-marked cells to differentiated 
mesenchymal skeletal cell types at adult stages, we performed co-labeling with markers 
for cartilage, bone, and adipose tissues. Hoxa11E13.5-lineage marked cells can be visually 
identified as differentiating into chondrocytes within the growth plate, co-staining with 
markers of differentiation identifies Hoxa11E13.5-lineage cells as osteoblasts on the 
trabecular and endosteal bone surfaces, osteocytes embedded within the cortical bone, and 
as adipocytes in the bone marrow [Figure 2.4a]. Analysis out to one year of age shows that 
Hoxa11E13.5-lineage marked cells continue to give rise to all skeletal lineages; 
chondrocytes, osteoblasts, osteocytes, as well as bone marrow adipocytes [Figure 2.4b]. At 
these stages, the growth plate has collapsed in mice, however Hoxa11E13.5-lineage marked 
chondrocytes are observed throughout the articular cartilage [Figure 2.4b, yellow bracket]. 
It is important to note that, in adult mice, osteoblasts are reported to live for one month, 
therefore multiple rounds of osteoblast turnover have presumably occurred between E13.5 
and 1 year of age110,134–136. 
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The same analyses were performed on Hoxa11P3-lineage marked stromal cells 
where essentially identical results are observed. Hoxa11P3-lineage marked cells 
differentiate into all mesenchymal skeletal cell types, including chondrocytes, osteoblasts, 
osteocytes, and bone marrow adipocytes [Figure 2.4c]. Hoxa11P3-lineage marked cells also 
continue to mark the same populations through one year of age [Supplemental Figure 2.4a]. 
 
Figure 2.4. Hoxa11-lineage contributes to all skeletal/mesenchymal cell types. (a-d) 
Pregnant dams received E13.5 and resulting Hoxa11eGFP;Hoxa11-CreERT2;ROSA-
tdTomato mice were chased to (a) 8 weeks or (b) 1 year. (c) P3 pups received tamoxifen 
and Hoxa11eGFP;Hoxa11-CreERT2;ROSA-tdTomato mice were chased to 8 weeks. All 
images, Hoxa11 lineage-labeled cells (Hoxa11iTom, red). Shown are chondrocytes with 
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characteristic columnar morphology at distal end of growth plate, osteoblasts stained with 
Osterix (white) on trabecular (top) and endosteal bone (bottom), osteocytes within the 
cortical bone stained with SOST (green), and bone marrow adipocytes stained with 
Perilipin (green). Dashed yellow lines mark upper and lower boundaries of growth plate, 
dotted yellow lines mark periosteal and endosteal boundaries of cortical bone. White 
dashed boxed region of single (a, c) or multiple (b) osteocytes(s) magnified to right. White 
dotted box of single adipocyte magnified to right. In all images, grey or blue: DAPI. Scale 
bars: (chondrocyte and adipocytes images) 100μm, (osteoblast and osteocyte images) 
50μm, (b, SOST) 25μm. 
 
Hoxa11-marked progenitors are maintained throughout life 
We next performed flow cytometry analyses on Hoxa11E13.5-lineage marked 
stromal cells from the zeugopod bone marrow and bone surfaces to assess the cell surface 
identity of these cells. The majority of Hoxa11E13.5-lineage marked stromal cells from both 
compartments were confined to the non-hematopoietic, non-endothelial stromal 
compartment (CD45-TER119-CD31-) [Supplemental Figure 2.3e]. Adult, Hoxa11E13.5-
lineage marked bone marrow stromal cells specifically express MSC markers 
PDGFRα/CD51 and LepR, demonstrating that the embryonically labeled Hoxa11-
expressing cells give rise to adult, progenitor-enriched MSCs that are maintained 
throughout life [Figure 2.5a]. Similar flow cytometry profiles are observed for Hoxa11E13.5-
lineage marked cells that persist on the cortical bone surfaces, with the majority of labeled 
bone surface stromal cells co-expressing PDGFRα/CD51 and LepR as we have previously 
reported for real-time expression of Hoxa11eGFP [Figure 2.5a and 86]. Hoxa11E13.5-lineage 
marked cells continue to co-express these MSC markers through one year of age and 
beyond [Figure 2.5b]. Additionally, a majority of Hoxa11E13.5-lineage marked cells co-
express Hoxa11eGFP [Figure 5a and Supplemental Figure 2.3f, g]. Collectively these data 
provide evidence that the embryonic Hoxa11-expressing cell population gives rise to 
Hoxa11eGFP-expressing MSCs that persist throughout the life of the animal. 
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The same analyses were performed on Hoxa11P3-lineage marked stromal cells and 
nearly identical results are observed. Flow cytometry analyses on adult, Hoxa11P3-lineage 
marked bone marrow and bone surface stromal cells demonstrate that Hoxa11P3-lineage 
marked cells are contained within the non-hematopoietic, non-endothelial stromal 
compartment and co-express progenitor-enriched MSC markers PDGFRα/CD51 and LepR 
in both the bone marrow and bone surface compartments and continue to co-express these 
MSC markers out to one year of age [Figure 2.5c-d and Supplemental Figure 2.4b]. 
Hoxa11P3-lineage marked cells also express Hoxa11eGFP in both compartments 
[Supplemental Figure 2.4c]. 
 
Hoxa11-lineage regenerates bone and cartilage upon fracture 
To examine whether Hoxa11-lineage marked cells serve as progenitors in regeneration and 
repair of the skeleton following injury, Hoxa11CreERT2;ROSA26-LSL-tdTomato animals 
were administered tamoxifen at E13.5 or at P3 to initiate lineage-labeling and the ulna was 
fractured at adult stages (8-10 weeks of age). Contribution to regenerating cartilage and 
bone was analyzed 10 days post-injury (10 DPI). Hox11E13.5- and Hoxa11P3-lineage 
marked cells expand in response to fracture and are observed throughout the callus [Figure 
2.6a, d]. Apparent expansion of both the periosteal stromal compartment and the bone 
marrow stromal compartment is observed. Hoxa11 lineage-marked cells give rise to both 
Sox9-positive chondrocytes within the cartilaginous regions of the callus and to Osx-
expressing osteoblasts within the woven bone regions of the callus [Figure 2.6b, c, e, f]. 
		 37	
 
Figure 2.5. Hoxa11-lineage marked progenitors are maintained throughout life  
Pregnant dams received E13.5 and resulting Hoxa11eGFP;Hoxa11-CreERT2;ROSA-
tdTomato mice were chased to (a) 8 weeks [n=3] or (b) 1 year [n=4]. P3 pups received 
tamoxifen and Hoxa11eGFP;Hoxa11-CreERT2;ROSA-tdTomato mice were chased to (c) 8 
weeks [n=6] or (d) 1 year [n=3]. Flow cytometry analyses of non-hematopoietic, non-
endothelial stromal compartment (CD45-TER119-CD31-, NES) in bone marrow (top 
panels) and bone surface (bottom panels). (a, c) First panel: Hoxa11 lineage-marked cells 
(x-axis: Hoxa11iTom), second panel: analysis of Hoxa11iTom positive gate (red) for 
Hoxa11eGFP expression, third panel: co-expression analysis of PDGFRα/CD51, fourth 
panel: co-expression analysis of Leptin Receptor (LepR-Ab). (b, d) Left: co-expression 
analysis of PDGFRα/CD51, right: co-expression analysis of Leptin Receptor (LepR-Ab). 
Percentages reflect proportion of Hoxa11iTom population in identified gate. Grey dots: 
total non-endothelial stroma (NES), red dots: Hoxa11iTom. ‘n’ values indicate biologically 
independent animals for each time point. All data presented as mean ± standard deviation. 
 
Contribution of Hoxa11-lineage marked cells to the regenerating skeletal tissues is 
qualitatively equivalent whether lineage-tracing is initiated at embryonic or postnatal 
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stages, demonstrating that Hoxa11-positive cells from both stages represent roughly 
equivalent, functional, adult skeletal MSCs. 
To test the continued functionality of the Hoxa11-lineage marked progenitor 
population throughout life, we allowed lineage-marked animals to age to 10 months prior 
to ulnar fracture. At late adult stages, the Hoxa11P3-lineage marked cell population expands 
robustly following injury and contributes to regenerating cartilage and bone 10DPI [Figure 
2.6g-i]. Additionally, the expanded lineage-marked stromal cells are Hoxa11eGFP-
positive, representing expanding progenitors as shown previously [Figure 2.6j and 86]. 
Lineage-marked cells within the periosteal region of the fracture callus are also periostin-
positive, consistent with expansion of Hox11-expressing periosteal stem cells following 
injury [Figure 2.6k]. 
Comparison of Hoxa11-lineage to other MSC populations  
A critical knowledge gap in the field is an understanding of the relationships 
between various identified MSC progenitor populations. Significant differences exist in the 
lineage-dynamics of these populations, yet the reasons for these differences are not clearly 
understood. We sought to establish the relationship between Hox11-expressing cells and 
previously reported MSC populations genetically labeled by LepR-Cre and Osx-CreER 
using our Hoxa11eGFP real-time reporter crossed to LepR-Cre;ROSA26-LSL-tdTomato 
mice or Osx-CreER;ROSA26-LSL-tdTomato mice. 
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Figure 2.6. Hoxa11-lineage cells regenerate skeleton following fracture. Ulnar fracture 
was performed at 8 weeks of age (a-f) or 10 months (g-k) on Hoxa11-CreERT2;ROSA-
tdTomato or Hoxa11eGFP;Hoxa11-CreERT2;ROSA-tdTomato mice following tamoxifen 
dosing at (a-c) E13.5 – to pregnant female, or (d-k) P3. (a, d, g) Hoxa11 lineage-positive 
cells (Hoxa11iTom, red) within the fracture callus 10 days post-injury (DPI). Fracture line 
marked with dashed yellow line and cortical bone (cb), bone marrow (bm), and periosteum 
(po) are labeled. Dashed white lines indicate regions visualized with antibodies (green) for 
cartilage (Sox9, b, e, h) and bone (Osx, c, f, i). Higher magnification of regions marked by 
dashed white lines (b, c, e, f) with channels separated shown to right. (j) Expression of 
Hoxa11eGFP (green) and Hoxa11iTom within the expanded stromal population. White 
dashed box magnified in inset. (k) Expression of Periostin (green) and Hoxa11iTom within 
the expanded periosteal compartment (bracket). In all images, grey: DAPI. Scale bars: (a, 
d, g) 500μm, (b-c, e-f) 200μm, (j) 100μm, (h-i, k) 50μm. 
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LepR-Cre lineage-marked cells first appear during late embryonic stages within the 
primary spongiosa [Figure 2.7a and 112,115,126]. At this stage, Hoxa11eGFP-expressing cells 
are more extensively observed throughout the periosteum and along the bone surfaces of 
the primary spongiosa. There is only very rare overlap between LepR-Cre lineage-marked 
cells and Hoxa11eGFP at early stages [Figure 2.7a, arrowheads]. The number of LepR-Cre 
lineage-marked cells increases markedly during postnatal development. In the bone 
marrow, the overlap between Hoxa11eGFP and LepR lineage-marked cells also 
progressively increases with age with more of the Hoxa11eGFP-positive cells also 
becoming LepR-positive [Figure 2.7b-e and Supplemental Figure 2.5]. By 15 weeks, the 
majority of Hoxa11eGFP-expressing bone marrow stromal cells are also LepR-lineage 
positive [Figure 2.7e and Supplemental Figure 2.5 and 86]. The number of LepR-Cre 
lineage-marked cells on the periosteal and endosteal bone surfaces also increases with age, 
however even as late as 15 weeks of age, only half of Hoxa11eGFP, bone-adherent cells 
are LepR-lineage positive [Figure 2.7b’-e’ and Supplemental Figure 2.5]. Interestingly, 
there is a population of Hoxa11eGFP-expressing cells on the outer perichondrial surface 
that remains LepR-Cre lineage-negative at all stages examined [Figure 2.7d’-e’, 
arrowheads]. These results are consistent with LepR-lineage labeling continuing to initiate 
in Hoxa11-positive cells [Figure 2.7f]. Differences in the overlap between the bone marrow 
and bone adherent populations reveal a unique Hoxa11-expressing population in the 
periosteum, perhaps explaining, at least in part, the earlier and more extensive Hoxa11-
lineage contribution to differentiated skeletal cells.  
Previous reports demonstrate Osx-lineage contribution to MSCs when induction is 
initiated at postnatal stages but the absence of long-term lineage contribution when induced 
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at embryonic stages115,127. We induced Osx-lineage labeling in Hoxa11eGFP;Osx-
CreER;ROSA26-LSL-tdTomato animals at E13.5 or at P3 to compare these populations to 
Hoxa11eGFP-expressing cells. One day following tamoxifen administration at E13.5, 
embryonic Osx-lineage (OsxE13.5) marked cells are restricted to the inner periosteal, pre-
osteoblast layer, while Hox11-expressing cells are restricted to  
 
Figure 2.7. LepR-Cre progressively marks existing Hoxa11eGFP-positive cells. 
Analysis of the co-expression of Hoxa11eGFP (green) and LepR-Cre lineage-marked cells 
(LepRiTom, red) in Hoxa11eGFP;LepR-Cre;ROSA-tdTomato mice. Percentages (yellow) 
reflect proportion of Hoxa11eGFP-positive cells that also express LepRiTom. Flow 
cytometry analyses shown in Supplemental Figure 5. (a) magnified view of primary 
spongiosa and developing cortical bone surface at E18.5 [n=3]. (b-e’) High magnification 
view of mid-diaphysis of ulna (b-e) bone marrow, or (b’-e’) cortical bone. (d’,e’) at 2 
[n=4], 4 [n=3], 8 [n=3], and 15 weeks [n=3]. Arrowheads identify non-overlapping 
Hoxa11eGFP-positive periosteal cells. In all images; grey: DAPI. Data presented as mean 
± standard deviation. ‘n’ values indicate biologically independent animals for each time 
point. (f) Diagram of data at E18.5, 2 weeks, and 15 weeks. All scale bars: 100μm. 
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the outer periosteal layer with little to no overlap observed [Figure 2.8a-b]. Osx-CreER 
lineage induction at E13.5 also labels hypertrophic chondrocytes in the developing bone. 
The pattern of OsxE13.5-lineage marked cells is consistent with Osterix protein expression 
using an anti-Osterix antibody [compare Figure 2.8b and Figure 2.1b]. By E18.5, OsxE13.5-
lineage marked cells are observed throughout the primary spongiosa and minimal co-
expression with Hoxa11eGFP is observed [Figure 2.8c-e, arrows]. Hoxa11eGFP-
expressing cells and OsxE13.5-lineage marked cells continue to exhibit an almost mutually 
exclusive stratified pattern in the periosteum, with OsxE13.5-lineage marked cells in the 
inner pre-osteoblast layer and Hoxa11eGFP the adjacent outer periosteal layer [Figure 
2.8e]. OsxE13.5-lineage marked cells and Hoxa11eGFP-expressing cells show a small 
degree of overlap in the adult bone marrow and on the endosteal bone surface [Figure 2.8f-
i]. However, OsxE13.5-lineage marked cells are rare at adult time points and represent only 
2.7±0.3% of the total Hoxa11eGFP-positive population [Figure 2.8i]. Flow cytometry 
analyses of the small population of bone marrow OsxE13.5-lineage marked cells shows 
74.0±3.4% co-express PDGFRα/CD51 and 69.3±8.3% co-expresses Hoxa11eGFP [Figure 
2.8i]. Virtually no OsxE13.5-lineage marked cells remain on the bone surfaces by adult 
stages, having presumably differentiated into osteoblasts and osteocytes by 8 weeks 
[Figure 2.8g, i]. As these two populations do not progressively overlap with age, these data 
reveal that the Hoxa11eGFP-positive perichondrial/periosteal population is distinct from 
the embryonic OsxE13.5-lineage marked cells [Figure 2.8j]. 
At the earliest stages of limb development, Hox11 expression is not confined to the 
zeugopod but is broadly expressed in the lateral plate mesoderm88. Tamoxifen was 
administered to Hoxa11-CreERT2;ROSA-tdTomato animals at E11.5 (Hox11E11.5), two days 
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prior to initiation of Osterix expression in the developing skeleton, and the contribution of 
Hoxa11E11.5-lineage marked cells to the skeleton was assessed. At E14.5, Hoxa11E11.5-
lineage marked cells have contributed significantly to the developing skeleton including 
Osx-positive osteoprogenitors within the developing periosteum [Figure 2.8k, inset]. There 
is additionally contribution to Sox9-positive chondro-progenitors throughout the distal 
growth plate consistent with Hox11-expressing cells serving as upstream progenitors for 
this population as well, as expected for a broad marker of lateral plate mesoderm [Figure 
2.8l]. Hoxa11E11.5-lineage marked cells continue to contribute extensively to the 
developing skeleton, including significant contribution to osteoblasts on the trabecular and 
cortical bone surfaces [Figure 2.8m-p]. These data show that the Hoxa11-lineage arises 
prior to the Osx-lineage, and that Hox11-expressing cells serve as primitive progenitors 
that give rise to early osteoprogenitor and the osteoblast lineage. 
Consistent with the reported progenitor capacity of the postnatal Osx-lineage 
marked population (OsxP3), some overlap is observed between Hoxa11eGFP-expressing 
cells and OsxP3-lineage marked cells at this stage. Three days following tamoxifen 
administration, OsxP3-lineage marked cells are localized to the bone surfaces (periosteal, 
endosteal, and trabecular) [Figure 2.9a-b]. The Hoxa11eGFP-expressing cells that are 
observed in the periosteum overlap with OsxP3-lineage marked cells at the innermost 
periosteal layer, but additional non-overlapping Hoxa11eGFP-positive cells are observed 
in the outer periosteum [Figure 2.9b]. Hoxa11eGFP-positive cells are also already present 
at this stage throughout the bone marrow space and no co-expression with rare OsxP3-
lineage marked bone marrow cells is observed [Figure 2.9c, arrow]. Following an 8-week 
chase, OsxP3-lineage marked cells contribute to bone, fat, and bone marrow stromal cells, 
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consistent with previous reports [Figure 2.9d-f and 115]. Most OsxP3-lineage marked cells 
in the bone marrow co-express Hoxa11eGFP and markers for progenitor-enriched MSCs, 
PDGFRα/CD51 [Figure 2.9f-g]. On the bone surfaces, only about half of OsxP3-lineage 
marked cells co-express PDGFRα/CD51 and Hoxa11eGFP [Figure 2.9e, g]. The remaining 
population likely reflects lineage-marked pre-osteoblasts. Interestingly, the majority of 
overlap between Hoxa11eGFP-expressing cells and OsxP3-lineage marked cells is observed 
on the endosteal surface, while a stratified, non-overlapping expression pattern continues 
to be observed on the periosteal surface [Figure 2.9d-e]. Of note, OsxP3-lineage marked 
cells at adult stages represent only a small fraction of the total Hoxa11eGFP-positive 
population, ~11% [Figure 2.9g]. These data show that Osx-CreER marks a sub-population 
of Hox11-expressing MSCs at postnatal stages that persist to adult stages [Figure 2.9h]. 
These data additionally highlight the unique Hox11-expressing population in the outer 
periosteum, adjacent to the Osx-positive inner pre-osteoblast periosteal layer that does not 
overlap with Osx-lineage marked cells at any stage examined. 
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Figure 2.8. Hoxa11eGFP-positive MSCs are distinct from embryonic Osx-lineage. 
Comparison of Hoxa11eGFP (green) and Osx-CreER lineage-marked cells (OsxiTom, red) 
was performed in Hoxa11eGFP;Osx-CreER;ROSA-tdTomato mice. (a-g) Pregnant 
females received tamoxifen at E13.5 and co-expression of Hoxa11eGFP and embryonic 
Osx-lineage was examined at (a-b) E14.5, (c-d) E18.5 and (f-i) 8 weeks. (a) Complete 
radius (r) and ulna (u) 24 hours after tamoxifen with proximal to the left and distal to the 
right. White box region magnified in (b) anlagen boundary indicated by dotted white line. 
(c) Mid-diaphysis ulna; white dashed boxes indicate magnified region of (d) primary 
spongiosa and (e) periosteum. (f) Mid-diaphysis tibia; white dashed boxes indicate 
magnified region of adult (g) endosteal surface and (h) bone marrow. (i) Flow cytometry 
analysis of non-hematopoietic, non-endothelial stroma (CD45-TER119-CD31-, NES) in 
bone marrow (top panels) and bone adherent (bottom panels) compartments. First panel: 
analysis of OsxiTom population for PDGFRα/CD51, second panel: analysis of OsxiTom 
for Hoxa11eGFP, third panel: analysis of Hoxa11eGFP-positive cells (green) for OsxiTom 
expression. OsxiTom cells are very rare (0.018±0.03 of total NES) on bone surface (lower 
left panel). n=3 biologically independent animals. Flow cytometry dot plots, grey dots: 
total non-endothelial stroma (NES). Data presented as mean ± standard deviation. (j) 
Diagrammatic representations of data. (k) Pregnant females received tamoxifen at E11.5 
and Hoxa11-CreERT2;ROSA-tdTomato embryos were analyzed at (k-l) E14.5 and (m-p) 
E18.5. (k) White boxed region shown in inset, co-expression of Hoxa11iTom (red) and 
Osterix (green). (m) white boxed region of primary spongiosa magnified in n. (n) white 
dashed boxes indicate magnified regions of (o) trabeculae and (p) periosteum. Periosteum: 
po, bone marrow: bm, cortical bone: cb, endosteum: endo All fluorescent images, grey: 
DAPI.  Scale bars: (a, f, k) 200μm, (b, d-e, g-h) 50μm, (c, i, n) 100μm, (o-p) 25μm. 
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Figure 2.9. Postnatal Osx-lineage marginally overlaps with Hoxa11eGFP-positive 
cells. Comparison of Hoxa11eGFP (green) and Osx-CreER lineage-marked cells 
(OsxiTom, red) was performed in Hoxa11eGFP;Osx-CreER;ROSA-tdTomato mice. P3 
pups received tamoxifen and co-expression of Hoxa11eGFP and postnatal Osx-lineage was 
examined at (a-c) P6 and (d-f) 8 weeks. (a) Mid-diaphysis ulna; dashed white boxes 
indicate magnified (b) cortical bone and (c) bone marrow, rare OsxiTom stromal cell 
(arrow). (d) Mid-diaphysis tibia, white dashed boxes indicate magnified (e) periosteum and 
(f) bone marrow. (g) Flow cytometry analysis of non-hematopoietic, non-endothelial 
stroma (CD45-TER119-CD31-) in bone marrow (top panels) and bone surface (bottom 
panels) compartments. First panel: analysis of OsxiTom population for PDGFRα/CD51, 
second panel: analysis of OsxiTom for Hoxa11eGFP, third panel: analysis of 
Hoxa11eGFP-positive cells (green) for OsxiTom expression. n=4 biologically independent 
animals. Flow cytometry dot plots, grey dots: total non-endothelial stroma (NES). Data 
presented as mean ± standard deviation. (h) Diagrammatic representations of data. 
Periosteum: po, bone marrow: bm, cortical bone: cb, endosteum: endo All fluorescent 
images, grey: DAPI. Scale bars: (a) 200μm, (b-c, e-f) 50μm, (d) 100μm. 
 
  
		 48	
Discussion 
Previous lineage analyses support a model whereby transient, embryonic, skeletal 
progenitors are replaced with bona fide adult skeletal stem cells that are established during 
early postnatal life107,137. A substantial caveat to many of these genetic tools is that 
tamoxifen-inducible Cre expression is driven by promoters for genes that function in early 
lineage commitment to skeletal cell types (for instance chondrocyte – Sox9-CreER, PthrP-
CreER, and Aggrecan-CreER, or osteoblast – Osx-CreER)115,127 (reviewed by 138). 
Therefore, the bulk of these lineage-marked cells will be committed to the chondrocyte or 
osteoblast fate while only a small population of progenitors will be marked by these alleles. 
Labeling of long-term skeletal progenitors by these models is incomplete and the temporal 
differences in MSC capacity observed likely reflects depletion of early committed 
progenitors over time. Other genetic models, driven by promoters of genes involved in key 
signaling pathways such as Hedgehog (Gli1-CreER), BMP (Gremlin1-CreER) or 
Parathyroid hormone-related protein (PthrP-CreER), also demonstrate temporal 
differences in progenitor capacity over time111,128,129. These signaling pathways are 
important for chondrogenic and osteogenic differentiation and differences in the progenitor 
capacity of these lineage-marked populations with time may reflect changes in the 
signaling environment of the skeleton and reporter/lineage expression, in these cases, 
would not be expected to specifically label the skeletal progenitor pool139–142.  
Prior reports establish that Hox expression is excluded from differentiated skeletal 
cell types at all stages and loss-of-function analyses at embryonic, postnatal, and adult 
stages provide evidence for Hox gene function in the skeleton throughout life85–87. Herein, 
we present evidence that Hox11-expressing stromal cells, marked by Hoxa11-CreERT2 
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from both embryonic and postnatal stages, specifically enrich for a population of skeletal 
progenitors throughout the life of the animal and are likely to encompass a bona fide 
skeletal stem cell population. In contrast to models asserting that developmental 
progenitors are later replaced by postnatally arising adult MSCs, these data reveal a 
lineage-continuous population that is maintained from embryonic through adult stages. 
Hoxa11 lineage-marked cells contribute extensively to the skeleton, giving rise to all 
skeletal cell types including chondrocytes, osteoblasts, osteocytes, and bone marrow 
adipocytes at all stages examined. Hoxa11 lineage-marked cells additionally persist within 
the bone marrow space and on the cortical bone surfaces throughout life and maintain co-
expression of MSC markers. Further, Hoxa11eGFP/Hoxa11 lineage-marked cells expand 
following fracture injury and contribute to regenerating cartilage and bone, even when 
injury is induced at late adult stages, demonstrating that Hox11-expressing MSCs 
functionally give rise to new skeletal cells throughout life. The collective evidence 
demonstrates a continuous lineage relationship between the embryonic and the adult 
Hox11-expressing skeletal progenitor, MSC population. The data provides in vivo evidence 
that the Hox11-expressing stromal population enriches for life-long, self-renewing skeletal 
MSCs. 
Assessing the relationship between different genetically-defined populations of 
skeletal progenitors is critical for understanding how these populations behave and can 
provide information on the spatiotemporal dynamics of skeletal stem cells. Hoxa11 
lineage-marked progenitors arise days prior to the differentiation of pre-osteoblasts (as 
defined by Osx expression that begins ~E13.5) or LepR-Cre (initiates ~E17.5). Given 
LepR-Cre is not a temporally controlled Cre, the progressive overlap of Hoxa11eGFP and 
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LepR-lineage marked cells suggest that LepR-Cre transgenic expression, and thus, the 
LepR-lineage, is increasingly initiated within the Hoxa11eGFP-positive population. Also, 
considering the adjacent but non-overlapping organization of Hoxa11eGFP-expressing 
cells and Osx-lineage marked cells in the periosteum, these data lead to the conclusion that 
Hox-expressing progenitors in the outer periosteum give rise to the population marked by 
Osx-CreER, and subsequently the complete osteo-lineage. These comparative experiments 
demonstrate that the Hoxa11eGFP-expressing stromal population serves as the upstream 
population that gives rise to populations labeled by Osx-CreER and LepR-Cre. 
Examination of the spatial overlap between Hoxa11eGFP-expressing cells and the 
populations marked by Osx-CreER or LepR-Cre revealed a Hoxa11eGFP-expressing 
population that is uniquely present in the outer periosteum. This population is non-
overlapping with either the LepR lineage-marked population or the Osx-CreER-marked 
population after short- or long-term lineage-labeling. The periosteal compartment has 
recently been shown to contain skeletal stem cells, identified by expression of periostin, 
with greater capacity to regenerate bone compared to bone marrow MSCs124. Hox11-
expressing cells in the inner periosteal layer overlap with the pattern of periostin 
expression, at homeostasis and following fracture, providing evidence to corroborate that 
this spatially defined sub-population of periosteal cells may be, at least in part, the bona 
fide skeleton stem cell population. Through a series of sophisticated transplantation studies, 
Duchamp de Lageneste et al. demonstrated that adult periosteal and adult bone marrow 
MSCs both derive from the local embryonic perichondrial/periosteal mesenchyme124. Our 
Hoxa11-lineage tracing data provides direct in vivo evidence that is in complete 
concordance with this conclusion. 
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We previously reported that adult bone marrow MSCs from different anatomical 
regions display a differential Hox expression profile. Specifically, each skeletal 
compartment maintains the Hox expression that is established during embryonic 
development86. Importantly, Hox expression in the adult bone marrow is confined to only 
progenitor-enriched MSCs. Hoxa11-CreERT2 allows for the unique, in vivo labeling of the 
zeugopod-restricted MSC population and shows that skeletal contributions of MSCs 
remain regional throughout life. Skeletal MSCs are not mobile; they remain at or near their 
site of origin. Our data support a model whereby regional, Hox-expressing stem cell 
populations in the skeleton are established during embryonic development and give rise to 
regionally-restricted, skeletal mesenchymal stem cells that self-renew and function 
throughout the life of the animal.  
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Supplemental Information 
 
 
Supplemental Figure 2.1. Bone adherent Hoxa11eGFP-positive cells express MSC 
markers PDGFRα/CD51 and Leptin Receptor. (a) Gating strategy to obtain non-
hematopoietic, non-endothelial stromal compartment. Example from adult (8-10wk) bone 
marrow. Strategy applies to data generated in Figures 2.2, 2.5, 2.7, 2.8i, and 2.9g and 
Supplemental Figures 1b, 3e, 4b, and 5. (b) Compliment to Figure 2a, flow cytometry 
analyses of bone adherent compartment (P14, 8 week, 6 month, and 1 year). Non-
hematopoietic, non-endothelial stromal compartment (CD45-TER119-CD31-) was gated 
on PDGFRα/CD51 (top) or Leptin Receptor (LepR-Ab, bottom). Percentages reflect 
proportion of Hoxa11eGFP-positive population within double positive gate (top) or 
bracketed region of histogram (bottom). Charcoal dots or grey histogram: total non-
endothelial stroma (NES), green dots or green histogram: Hoxa11eGFP-expressing non-
endothelial stroma (Hoxa11eGFP+). All data presented as mean ± standard deviation. (c) 
Gating strategy to obtain mouse skeletal stem cell (mSSC) population (CD45-TER119-
CD31-αV+Thy-6C3-CD105-CD200+) from non-endothelial stroma population. Strategy 
applies to Figure 2.2b-c. 
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Supplemental Figure 2.2. Cas9/CRISPR generation of a Hoxa11-CreERT2 allele: (a) 
Schematic of Cas9/CRISPR targeting of Hoxa11 locus for generation of Hoxa11-CreERT2 
allele. Top: Hoxa11 locus, positions and sequence of sgRNAs (grey box: PAM), Nco1 
restriction sites, positions for 5’ and 3’ Southern Blot probes and size of wild-type (WT) 
fragment generated. Middle: Hoxa11-CreERT2 targeting vector, 5’ and 3’ homology 
regions (thick black line), CreERT2 and rabbit globin poly-adenylation (PA) insertion 
(red), and location of Cre PCR primers. Bottom: Hoxa11-CreERT2 allele, Nco1 restriction 
sites, positions for 5’, 3’ and Cre Southern Blot probes and size of edited fragments 
generated. (b) PCR analysis for Cre sequence on 29 live births. (c) Southern Blot on four 
Cre-positive animals using 5’ probe (top), 3’ probe (middle) and Cre probe (bottom). Wild-
type and edited bands and sizes as marked. (d) CreERT2 recombination in the absence of 
tamoxifen in Hoxa11-CreERT2;ROSA-tdTomato mice at 6 weeks of age. Fluorescent 
image - red: Hoxa11 lineage-marked cells (Hoxa11iTom), grey: DAPI. 
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Supplemental Figure 2.3. Embryonic Hoxa11-lineage contributes to the skeleton 
during development and marked stromal cells co-express Hoxa11eGFP and persist 
throughout life. Pregnant dams received tamoxifen at E13.5 and resulting 
Hoxa11eGFP;Hoxa11-CreERT2;ROSA-tdTomato mice were chased to (a) E16.5, (b-d) 
E18.5 (e-f) 8 weeks or (g) 1 year. (a) Hoxa11eGFP (green) expression and lineage 
contribution of Hoxa11 lineage-marked cells (Hoxa11iTom, red) in forelimb (humerus (h), 
radius (r), and ulna (u)). Compliment to Figure 3f. (b) High magnification view of ulna 
growth plate. Dashed white boxes show approximate location of high magnification images 
(c-d). Co-expression of Hoxa11iTom and Osterix (white) in (c) primary spongiosa (d) 
periosteum (po). (e) Flow cytometry analyses of Hoxa11iTom cells in the hematopoietic 
(left, CD45+TER119+) and endothelial (right, CD45-TER119-CD31+) compartments in 
the bone marrow. Flow cytometry data presented as mean ± standard deviation. 
Percentages reflect proportion of Hoxa11iTom population within identified gate. Grey 
dots: total non-endothelial stroma (NES), red dots: Hoxa11iTom. (f) Co-expression of 
Hoxa11iTom and Hoxa11eGFP in the bone marrow (left) and on the bone surface (right). 
Cortical bone: cb, bone marrow: bm, dashed white line marks endosteal (endo) bone 
surface. (g) Hoxa11eGFP in Hoxa11iTom bone marrow stromal cells after one-year chase. 
All images, grey or blue: DAPI. 
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Supplemental Figure 2.4. Postnatal Hoxa11-lineage contributes to all 
skeletal/mesenchymal lineages at 1 year. P3 pups received tamoxifen and 
Hoxa11eGFP;Hoxa11-CreERT2;ROSA-tdTomato mice were chased to (a) 1 year or (b-c) 
8 weeks. (a) Hoxa11 lineage-marked cells (Hoxa11iTom, red) within articular cartilage, 
and immunolabeling for osteoblasts (Osterix, white) on endosteal bone surface, osteocytes 
(SOST, green) in cortical bone, and adipocytes (Perilipin, green) in bone marrow. Articular 
chondrocytes marked by yellow bracket. (b) Flow cytometry analyses of Hoxa11iTom 
cells in the hematopoietic (left, CD45+TER119+) and endothelial (right, CD45-TER119-
CD31+) compartments in the bone marrow. Flow cytometry data presented as mean ± 
standard deviation. Percentages reflect proportion of Hoxa11iTom population within 
identified gate. Grey dots: total non-endothelial stroma (NES), red dots: Hoxa11iTom. (c) 
Hoxa11iTom and Hoxa11eGFP (green) in bone marrow (left) and on bone surface (right). 
Bone marrow: bm, cortical bone: cb, white dashed lines mark periosteal and endosteal 
(endo) surfaces. All images, blue or grey: DAPI. 
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Supplemental Figure 2.5. LepR-Cre lineage progressively overlaps with Hoxa11eGFP-
positive population. Flow cytometry analyses of Hoxa11eGFP-expressing stromal cells 
(green) and LepR-Cre lineage (LepRiTom) in whole bone at P0, or bone marrow (top) and 
bone adherent (bottom) compartments from P14 to 15 weeks. Analysis in non-
hematopoietic, non-endothelial (CD45-Ter119-CD31-) compartment. Percentages reflect 
proportion of Hoxa11eGFP-positive population within indicated gate. All data presented 
as mean ± standard deviation.  
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Materials and Methods 
Mouse models 
 All mice were maintained in a C57BL/6 background. Hoxa11eGFP133, Leptin 
Receptor-Cre143, Osterix-CreERT2 52, mice have been described elsewhere. Rosa26-CAG-
loxp-stop-loxp-tdTomato (144, JAX stock #007909) were obtained from Jackson 
Laboratory.  Both male and female mice were used for experiments. Animals were 
sacrificed for experiments through CO2 exposure followed by removal of a vital organ. All 
procedures described here were conducted in compliance with the University of 
Michigan’s Committee on Use and Care of Animals, protocol PRO00006651 (Wellik) and 
protocol PRO00006763 (Goldstein). 
Generation of Hoxa11-CreERT2 mice 
 Two guide sequences targeting exon 1 of Hoxa11 were designed and cloned into 
the pT7-Guide Vector (Blue Heron Biotech, LLC). The guide sequence and approximate 
locations of both sgRNA’s, including the corresponding PAM sequence, are illustrated in 
Supplemental Figure 2a. MEGAshortscript T7 kit (Life Technologies) was used to generate 
in vitro transcribed sgRNA’s from the pT7-Guide Vector and products were subsequently 
purified using the MEGAclear kit (Life Technologies). Using the pT7-Cas9-Nuclease 
vector (gift from Dr. Moises Mallo), Cas9 mRNA was in vitro transcribed using the 
mMESSAGE mMACHINE T7 ULTRA kit (Life Technologies) and purified using the 
MEGAclear kit (Life Technologies). 
 Homologous sequences flanking exon 1 of Hoxa11 were synthesized by Blue 
Heron Biotech, LLC into the pUCminusMCS vector as a continuous insert separated by 
sequence containing restriction sites for EcoRI, NotI, and HindIII to allow for sub-cloning 
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of CreERT2 and rabbit β-globin poly-adenylation signal. The 5’ homology arm contained 
1.3kb immediately upstream of the endogenous Hoxa11 start site and 3’ homology arm 
contained 1.3kb of sequence immediately downstream of sgRNA 2 as illustrated in 
Supplemental Figure 2a. Sequence for CreERT2 and rabbit β-globin poly(A) signal was 
sub-cloned from pCAG-CreERT2 vector (gift from Connie Cepko, Addgene plasmid 
#14797, 132). Targeting of CreERT2 to Hoxa11 locus preserved endogenous upstream and 
downstream sequence and creates a null allele; expressing CreERT2 in place of Hoxa11. 
 Zygote injections were performed as previously described with minor 
modifications145. C57BL/6 female mice were superovulated and mated with C57Bl/6 male 
mice and one-cell stage embryos were collected for microinjection. CRISPR reagents were 
microinjected at the following concentrations: Cas9 mRNA (100ng/μL), each sgRNA 
(50ng/μL), and targeting plasmid (20ng/μL). Freshly injected eggs were transferred into 
pseudopregnant females and resulting progeny were initially screened for potential 
CreERT2 insertion via PCR. The following internal primers for CreER sequence were used: 
Cre Fwd: 5’ GGACATGTTCAGGGATCGCCAGGC 3’, Cre Rev: 5’ 
CGACGATGAAGCATGTTTAGCTG 3’. Approximate location of primers indicated in 
Supplemental Figure 2a. Cre-positive animals by PCR were analyzed by Southern Blotting 
to confirm targeting using 5’ and 3’ flanking probes and a Cre internal probe with Nco1 
digested DNA. Approximate locations of probes are illustrated in Supplemental Figure 2a. 
The 453 bp 5’ probe was generated using primers: 5’ probe Fwd: 5’ 
TTTCGGTTCTCCTAGACGCC 3’ and 5’ probe Rv: 5’ CACGGCGTTTGCATGAGATT 
3’, the 533 bp 3’ probe was generated using primers: 3’ probe Fwd: 5’ 
TCTGTAGTGAGCGCCTTTGG 3’ and 3’ probe Rv: 5’ 
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GAGGTTCCCGAGAGACTCCT 3’, and the 408 bp Cre probe was generated using 
primers: Cre probe Fwd: 5’ GCATTACCGGTCGATGCAACGAGTGATGAG 3’ and Cre 
probe Rv: 5’ GAGTGAACGAACCTGGTCGAAATCAGTGCG 3’, that were randomly 
labeled with 32P-dCTP. Four animals were CreER positive via PCR and three animals 
showed correct targeting via Southern Blot [Supplemental Figure 2b-c]. Animal #27 
displayed germline transmission of the allele. Animals from this founder were used in all 
subsequent experiments. 
Tamoxifen treatment 
 For embryonic induction, Hoxa11-CreERT2 or Osx-CreERT2 male mice were 
mated to RosatdTomato/tdTomato or Hoxa11eGFP;ROSAtdTomato/tdTomato female mice and the 
vaginal plug was checked every morning. Pregnant mice received 2mg of tamoxifen 
(Sigma T5648) and 1mg/mL progesterone (Sigma P0130) dissolved in corn oil 
intraperitoneally at indicated embryonic day. For postnatal induction, pups of the genotype 
indicated in figures received 0.25mg of tamoxifen intragastrically at P3. At least three 
embryos, pups, or adult animals of the indicated genotypes were examined at time points 
shown in figures. 
Ulnar fracture 
 Following procedure previously described in detail86. Tamoxifen was administered 
as described above, and animals were aged to adult stages (8-10 weeks or 10 months). 
Briefly, animals were anesthetized with isoflurane during procedure and provided 
buprenorphine pre- and postoperatively and carprofen during recovery period. A small 
incision was made along the posterior ulnar surface and the bone was exposed via blunt 
dissection. Using fine wire cutters, the ulna was cut at the mid-shaft. Skin was closed using 
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sutures. Animals were sacrificed for analysis at 10 days post injury. At least three animals 
from each tamoxifen induction time point were examined. 
Immunohistochemistry 
 Limb skeletal tissues were collected at the indicated ages or time point following 
fracture injury. All specimens were dissected in PBS on ice and skin was removed prior to 
fixation for postnatal and adult tissues. Samples were fixed in 4% paraformaldehyde in 
PBS (embryo: 1-3 hours, postnatal (P3-P7): 4-6 hours, adult (2wk+): 1-2 days) rocking at 
4°C. Postnatal and adult tissues were decalcified in 14% EDTA for 1-7 days depending on 
age. Samples were equilibrated in 30% sucrose overnight prior to embedding into optimal 
cutting temperature medium. Cryosections were collected at 12-30 μm through indicated 
segments of the limb or fracture callus using the Kawamoto tape method146. 
Immunohistochemical staining was performed using standard methods. Sections were 
blocked with donkey serum and incubated with primary antibodies overnight at 4°C against 
Sox9 (Millipore, AB5535, 1:500), Osterix (Abcam, ab22552, 1:300), and Perilipin (Sigma, 
P1873, 1:100). Secondary antibodies were incubated at room temperature for 2 hr: donkey-
anti-rabbit-Alexa Fluor 647 (Thermo Fisher, A31573, 1:1000) and donkey-anti-rabbit-
Alexa Fluor 488 (Thermo Fisher, A21206, 1:1000). A modified signal amplification 
protocol was used to visualize SOST.  Following blocking, primary antibody against SOST 
(R&D Systems, AF1589, 1:100) was incubated overnight at 4°C followed by donkey-anti-
goat-biotin secondary (Jackson ImmunoResearch, 705-067-003, 1:400). The biotinylated 
secondary was detected using Vectastain Elite ABC kit (Vector Laboratories, PK-6100) 
and signal was amplified by Alexa Fluor 488 Tyramide reagent (Thermo Fisher, B40853). 
To minimize imaging complications from autofluorescence in postnatal and adult tissues, 
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Hoxa11eGFP was visualized using chicken-anti-GFP (Abcam, ab13970, 1:2000) and 
donkey-anti-chicken-Alexa Fluor 488 (Invitrogen, A11039, 1:1000) in combination with 
aforementioned antibodies. tdTomato expression was dim at 24-72hr post-tamoxifen 
induction and was visualized using rabbit-anti-RFP (Rockland, 600401379, 1:1000) and 
donkey-anti-rabbit-Alexa Fluor 555 (Invitrogen, A31572, 1:1000). Following longer 
chases, tdTomato was imaged directly without the use of an antibody. 
 Fluorescent images were captured on an Olympus BX-51 microscope with an 
Olympus DP-70 camera or Leica Upright Sp5x 2-photon confocal microscope. Confocal 
z-stacks were obtained through entire sections at a thickness of 2 μm and images were 
stacked using ImageJ software. When applicable, 10x images were stitched together using 
Photoshop software to obtained images of entire limbs and fracture calluses. 
Flow cytometry analysis 
 Bone marrow cells were harvested by flushing the marrow cavity with digestion 
buffer (2 mg/mL collagenase IV and 3 mg/mL dispase in 1X PBS) using a 30G needle for 
both the radius and ulna. To obtain bone adherent cells, the remaining bone following bone 
marrow flushing was minced in digestion buffer and subjected to subsequent digestion. 
The digestion of all samples was carried out at 37°C with three rounds of agitation to 
achieve a single cell suspension. After each cycle of digestion/agitation, cells in suspension 
were collected into media (DMEM, 10% calf serum) and kept at 37°C until the entire 
digestion protocol was finished. Red blood cells were lysed on ice using lysis buffer at a 
final concentration of 1X. For staining, cells were resuspended in staining buffer (1X PBS, 
0.5% BSA, 2mM EDTA) at a concentration of 1 x 106 cells/30μl in a solution containing 
the following antibodies. For hematopoietic exclusion: CD45-AF700 (eBioscience, clone 
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30-F11, 1:100) and TER119-APC-Cy7 (Becton Dickinson, clone TER119, 1:100). For 
endothelial cell exclusion: CD31-PerCPCy5.5 (Becton Dickinson, clone MEC13.3, 1:100). 
For MSC identification: PDGFRα/CD140a-APC (eBioscence, clone APA5, 1:100) and 
biotinylated rat-anti-CD51 (Biolegend, clone RMV-7, 1:100) or biotinylated goat-anti-
leptin receptor (R&D, BAF497, 1:50) and streptavidin-Brilliant Violet 605 (Biolegend, 
405229, 1:500). For mSSC identification: CD90.1-Brilliant Violet 510 (Biolegend, clone 
OX-7, 1:100), CD90.2-Brilliant Violet 510 (Biolegend, clone 53-2.1, 1:100), Ly51-
PerCPCy5.5 (Biolegend, clone 6C3, 1:100), CD200-PE (Biolegend, clone OX-90, 1:100), 
CD202b-APC (Biolegend, clone TEK4, 1:100). Following staining on ice, all samples 
were washed twice with staining buffer and resuspended in staining buffer containing 
DAPI (1:10,000) for analysis. All analyses were carried out on an LSRII Fortessa flow 
cytometer (BD) and results were analyzed with FlowJo (v10.2) software. Gating strategy 
outlined in Supplemental Figure 1a, c. Results are presented as mean values ±standard error 
of the mean (SEM). No statistical method was used to predetermine sample size. Sample 
size was determined on the basis of previous literature and our previous experiments to 
give sufficient standard error of the mean, and feasible generation of experimental animals. 
N-values represent number of animals in each analyses. The experiments were not 
randomized and investigators were not blinded during experiments and assessment of 
results. 
Data Availability 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request  
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CHAPTER III 
 
Hox Genes Function in the Adult Mammalian Skeleton 
 
Summary 
Hox genes are indispensable for the proper patterning of the skeletal morphology of the 
axial and appendicular skeleton during embryonic development. Recently, it has been 
demonstrated that Hox expression continues from embryonic stages through postnatal and 
adult stages exclusively in a skeletal stem cell population. However, whether Hox genes 
continue to function after development has not been rigorously investigated. Using a 
newly generated Hoxd11 conditional allele and conditional loss-of-function analyses, we 
show that Hox11 genes play critical roles in the skeletal homeostasis of the forelimb 
zeugopod (radius and ulna). Conditional loss of Hox11 function at adult stages leads to 
replacement of normal lamellar bone with an abnormal woven bone-like matrix of highly 
disorganized collagen fibers. Examining the lineage from the Hox-expressing mutant 
cells demonstrates no loss of stem cell population. Differentiation in the osteoblast 
lineage initiates with Runx2 expression, which is observed similarly in mutants and 
controls. With loss of Hox11 function, however, osteoblasts fail to mature with no 
progression to osteopontin or osteocalcin expression. Osteocyte-like cells become 
embedded within the abnormal bony matrix, but they completely lack dendrites as well as 
the characteristic lacuno-canalicular network and do not express SOST. Together, our 
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studies show that Hox11 genes continuously function in the adult skeleton in a region-
specific manner by regulating differentiation of Hox-expressing skeletal stem cells into 
the osteolineage.  
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Introduction 
Hox genes are important transcription factors responsible for establishing 
vertebral axial morphology along the anteroposterior (AP) axis during embryogenesis16. 
Additionally, the Hox9-Hox13 paralogs are indispensable for development of the 
proximodistal (PD) axis of the limb20,25–27. The Hox11 paralogous group, Hoxa11, 
Hoxd11 and Hoxc11, regulate the patterning of the sacral region of the vertebral column 
and the zeugopod skeleton of the forelimb and hindlimb (radius/ulna, tibia/fibula)20,25. 
Hox paralogous genes functionally compensate for one another in skeletal patterning and 
all paralogs expressed in a region need to be removed for defects to fully manifest. In the 
forelimb, the Hoxa11 and Hoxd11 paralogs are expressed, thus the removal of these two 
genes lead to a severe malformation of the zeugopod skeletal elements20,25. 
Using a Hoxa11eGFP reporter knock-in allele, we have shown that Hox 
expression initiates broadly at ~E9.5 within the developing limb bud mesenchyme, but 
very quickly becomes restricted to the zeugopod region88,133. While previous work has 
focused largely on the embryonic role of Hox genes, we observed that expression is 
continuous in the skeleton and extends beyond development into postnatal and adult 
stages85–88,147. Importantly, Hox expression remains regionally restricted and maintains 
the expression pattern that has been established during development68,86,148. Conditional 
adult loss-of-function has not been examined, but Hox11 compound mutants (animals in 
which three of the four paralogs are mutated) display normal embryonic development. 
However, compound mutants begin to exhibit skeletal growth phenotypes at postnatal 
stages and adults are not able to enact proper fracture repair, consistent with potential 
continuing functions85–87. The interpretation of this phenotype is complicated by the fact 
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that three alleles are absent throughout embryonic development, making it is impossible 
to separate embryonic defects that manifest later in life from continued function at adult 
stages.  
We previously demonstrated that Hox11 expression in the skeleton is exclusively 
restricted to a population of regional, progenitor-enriched mesenchymal stem/stromal 
cells (MSCs)86,147. Using a Hoxa11-CreERT2 lineage-tracing system, we recently 
established that the Hox11 lineage contributes to the development, growth and 
homeostasis of the zeugopod skeleton by giving rise to all of the mesenchymal lineages 
in the bone—osteoblasts, osteocytes, chondrocytes, and bone marrow adipocytes. 
Notably, this Hox11-expressing cell population is also maintained as self-renewing adult 
stem cells throughout life, demonstrating that Hox-expressing cells are bona fide skeletal 
stem cells (SSCs), continuously supplying the progenitors for bone maintenance and 
repair throughout the life of the animal147.  
While these previous studies have provided rigorous information on the Hox-
lineage, they have not addressed whether Hox function is required at later stages. This 
study sought to examine whether Hox genes continue to function in the adult skeleton 
within the skeletal stem cell population. In order to interrogate this potential, we 
generated a conditional Hoxd11 allele that, when combined with a Hoxa11 null allele, 
allows us to delete Hox11 function at any stage. We find that deleting Hox11 function at 
adult stages results in a progressive and dramatic remodeling of the zeugopod skeleton. 
Using our Hoxa11-CreERT2 allele to simultaneously delete Hox11 function and lineage-
label Hox11 mutant cells, we establish that the phenotype spatiotemporally correlates 
with the initiation of Hox11 deletion. Adult conditional mutants accumulate woven bone-
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like matrix with disorganized collagen that progressively replaces normal lamellar bone. 
Further, we find that the Hox11 conditional mutant animals generate pre-osteoblasts, but 
osteoblasts and osteocytes do not fully mature. For the first time, we establish that Hox 
genes do not functionally solely as embryonic patterning factors in the skeleton but 
continue to play an important role throughout life.  
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Results 
 
Regional adult Hoxa11-expressing skeletal stem cells continuously contribute to the adult 
zeugopod skeleton 
During development, Hox11 expression is restricted to the zeugopod region 
where it is observed in the perichodrium region surrounding the developing cartilage 
anlage88. Hox11 expression continues in cells present in the perichondrium/periosteum as 
the skeleton develops, also becoming visible on the endosteal bone surface, trabecular 
bone surface as well as in bone marrow stromal cells as the bone marrow space is created 
during late embryogenesis86,147. This expression pattern is then maintained throughout 
life86 (Figure 3.1A, inset). Our previous work demonstrated that  embryonic and 
postnatal Hox11-expressing cells are regionally-restricted skeletal stem cells and that this 
lineage provides progenitors for all skeletal mesenchymal lineages as well as exhibits 
continuous self-renewal as stem cells throughout life147. As expected, this lineage and 
behavior is recapitulated when lineage labeling is initiated at adult stages. By inducing 
lineage labeling at adult stages in Hoxa11-CreERT2;ROSA-LSL-tdTomato  animals, we 
show downstream lineage cells become osteoblasts on the trabecular as well as endosteal 
bone surfaces, and sclerostin-expressing osteocytes embedded within the cortical bone 
(Figure 1B, C; Supplemental Figure 3.1A, B).  
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Figure 3.1. Adult Hox11-expressing skeletal stem cells continuously give rise to 
osteoblasts and osteocytes. (A) Hoxa11-eGFP real-time reporter allele demonstrates 
continuous expression of Hoxa11 (green) at 12-weeks of age. t = tendon, D = distal, P = 
proximal. DAPI: gray. Scale bar: 200µm. A higher magnification image of the boxed 
area in (A) showing localization of Hoxa11 expression (green) in the periosteum, 
endosteum, and bone marrow compartment. PO = periosteum, CB = cortical bone, endo = 
endosteum, BM = bone marrow. DAPI: blue. Scale bar: 75µm. Animals of the indicated 
genotype were fed on tamoxifen chow at 8-10 weeks of age for a duration of 3 weeks to 
induce deletion and collected after a 6-month chase at 8-months of age. (B) Approximate 
location marked with a white box with corresponding letter in (A). Hoxa11-lineage 
marked cells (red) are found in the trabecular bone co-expressing osterix (white, green 
arrows). Yellow dashed line outlines the cortical bone and white dashed line demarcates 
the growth plate border. gp= growth plate. DAPI: blue. Scale bar: 75µm. (C) 
Approximate location marked with a white box with corresponding letter in (A). Hoxa11-
lineage marked cells (red) are also found as osteocytes embedded within the cortical bone 
co-expressing SOST (green). Hoxa11-lineage marked cells and DAPI (gray) in the far-
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left panel, SOST (green) and DAPI (gray) in the middle panel, and the merged image is 
shown in the far-right panel. Scale bar: 60µm. All images, PO = periosteum, CB = 
cortical bone, endo = endosteum, BM = bone marrow.  
 
Cas9/CRISPR generation and functional validation of a conditional Hoxd11 allele 
 To induce loss of Hox11 function at adult stages after the normal development 
and growth of the zeugopod skeleton, we generated a Hoxd11 conditional allele. As all 
Hox genes contain two exons with the DNA-binding homeodomain present in exon 2, we 
flanked exon 2 with loxP sites using CRISPR/Cas9-mediated gene editing145. Cre-
mediated removal of exon 2 is expected to lead to loss-of-function of Hoxd11 (Figure 
3.2A). In brief, two guide RNAs were targeted to regions of low conservation 5’ and 3’ 
of Hoxd11 Exon 2 and single stranded oligo donors were designed containing loxP 
sequence and 60bp of flanking homology sequence on each side for targeted insertion of 
LoxP sites flanking Hoxd11 Exon 2. The loxP sites were targeted sequentially to the 
locus to generate a Hoxd11 conditional allele through two rounds of zygote 
microinjection. Targeted insertion of each loxP site was confirmed by PCR and 
subsequent sequencing (Supplemental Figure 3.2A, B). 
The Hoxd11 conditional allele was first assessed for deletion of the region flanked 
by the loxP sites. Females with the genotype Hoxa11eGFP/+;Hoxd11loxP/loxP were mated to 
males with the genotype ROSACreERT2/+;Hoxa11+/-;Hoxd11loxP/loxP to generate embryos 
with the genotype ROSACreERT2/+;Hoxa11eGFP/-;Hoxd11loxP/loxP. PCR analyses on 
embryonic tissue were performed and the Hox11 conditional mutant embryos produced a 
robust recombined band and an absence of a detectable control band indicating efficient 
deletion (Figure 3.2B).  
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To functionally validate this new allele, we deleted Hoxd11 at embryonic stages 
in the background of Hoxa11 null mutants. It is important to note that the Hoxa11-eGFP 
allele is a knock-in that renders it non-functional. Therefore, animals that carry the 
genotype Hoxa11eGFP/- are functionally null for Hoxa11 but their forelimbs are 
indistinguishable from that of wildtype littermates from embryonic through adult stages 
serving as a good control for the conditional mutants (compare Figure 3.2C, D)25. We 
induced deletion by feeding pregnant dams tamoxifen chow for 1 week beginning at 
E9.5. This stage is approximately when Hox11 expression begins within the limb bud, 
therefore should recapitulate the Hox11 null phenotype when loss-of-function of Hox11 
is induced at this stage. Resulting embryos were collected at E17.5 and skeletal 
preparations demonstrated that Hox11 conditional mutants phenocopy Hoxa11-/-; 
Hoxd11-/- mutants, confirming that the Hoxd11 conditional allele results in deletion of 
Hoxd11 function (Figure 3.2E, F).  
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Figure 3.2. Conditional deletion of Hox11 function recapitulates the germline null 
mutation. (A) Cartoon schematic illustrating the Hoxd11 locus. Two guide RNAs with 
the indicated sequences (underlined) along with their corresponding PAM (highlighted 
blue) were used to flank exon 2 of Hoxd11 in order to insert loxP sites. Homology 
sequence used in the donor sequences are highlighted with thick dark blue line (5’ loxP) 
and thick light blue line (3’ loxP). Red arrows mark the location of the PCR primers used 
to confirm recombination. Corresponding PCR product sizes are indicated as well. The 
PCR elongation time was adjusted so that a 300bp PCR product would appear only if 
recombination had occurred between the loxP sites. Pregnant dams were fed on 
tamoxifen chow for 1 week to induce recombination and the resulting embryos were 
collected at E17.5. (B) PCR analysis using the PCR primers produce a robust 600bp 
control band only present in the controls and a 300bp recombined band only present in 
the conditional mutants. Skeletal preparations of limbs from (C) wildtype,  (D) 
littermate control for Hox11 conditional mutant, (E) Hox11ROSACreERT2 conditional 
mutant, and (F) Hox11 germline null mutant. Red box highlights the zeugopod skeleton. 
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Adult deletion of Hox11 function results in a progressive replacement of lamellar bone 
with abnormal bony matrix 
To assess the role of Hox11 during adult skeletal homeostasis, animals with the 
genotype ROSACreERT2/+;Hoxa11eGFP/-;Hoxd11loxP/loxP (referred to as Hox11ROSACreERT2 
conditional mutants) and corresponding controls (including animals of identical genotype 
minus the ROSA26-CreERT2 with tamoxifen administration, and animals with the 
ROSA26-CreERT2 in the absence of tamoxifen administration) were examined. Of note, 
there was minimal recombination in the absence of tamoxifen administration in animals 
with ROSA26-CreERT2 allele; these animals did not produce a phenotype nor show any 
evidence of recombination at the Hoxd11 locus as assessed by PCR (Supplemental 
Figure 3.2C, D).  
 Both control and conditional mutant adult animals were fed tamoxifen chow for 3 
weeks beginning at 8-10 weeks of age and chased for 2, 4, or 10 months after the 
initiation of deletion. Tail samples were processed to use for PCR analysis and confirmed 
high levels of recombination out to the 1-year time points (Figure 3.3A). Notably, 
recombination was measured at the same degree in tail samples as in the zeugopod 
skeleton (Supplemental Figure 3.2E).  A few of the Hox11ROSACreERT2 conditional 
mutants displayed a residual WT band, indicating incomplete recombination however, 
qRT-PCR analyses revealed robust loss of Hoxd11 in all cases (Figure 3.3B). Despite 
robust loss-of-function, it is critical to note that the Hox11-expressing skeletal stem cells 
are maintained in the conditional mutant bones out to the 1-year old time points as 
supported by continued Hoxa11eGFP expression (Supplemental Figure 3.3A, B). 
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MicroCT measurements did not reveal significant distinctions between the control 
and Hox11ROSACreERT2 conditional mutants at 6 months of age (four months after deletion, 
Supplemental Figure 3.4A, B). However, histological inspection revealed progressive 
changes in the appearance of the cortical bone in Hox11ROSACreERT2 conditional mutants 
compared to controls. Conditional mutant bones become notably hypercellular, and 
quantification revealed significantly higher cell numbers in the abnormal bony matrix 
(Figure 3.3C-I). Presumed osteocytes embedded within the hypercellular matrix 
displayed a round morphology compared to the ellipsoid morphology in controls (Figure 
3.E, inset). This phenotype resembles the histology of woven bone, which has a higher 
density of osteocytes within its matrix along with the round shape of the lacunae149. It is 
important to note that these abnormalities remain regionally restricted as the humerus of 
Hox11ROSACreERT2 conditional mutants was not affected even as late as the 1-year time 
point (Figure 3.3J, K).  
 
Abnormal bony matrix in adult Hox11 conditional mutants display disorganized collagen  
 The shape of osteocyte lacunae is strongly influenced by the orientation of the 
collagen fibers within the bone. Normal adult bone is comprised of lamellar bone with 
collagen fibers arranged in organized parallel sheets or layers and this contributes to the 
ellipsoid shape of the lacunae55,150. Woven bone, in contrast, is characterized by a 
haphazard organization of collagen fibers and contain osteocyte lacunae with a spherical 
shape, similar to what is observed in the Hox11 conditional mutants. The collagen 
network within cortical bone can be visualized by picrosirus red stain. Picrosirius red 
increases the birefringence of the collagen fibers and subsequent observation under 
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polarized light reveals the organization of the collagen network151,152. The picrosirirus red 
staining in control bone demonstrates a well-organized, parallel structure of collagen 
fibers characteristic of normal, mature lamellar bone, while the Hox11ROSACreERT2 
conditional mutant bones displayed a striking disorganization of the collagen matrix that 
correlates exactly with the hypercellular region (Figure 3.4A-F). Notably, both the 
region of disorganized collagen matrix and the hypercellular region increase with longer 
chases after deletion. (Figure 3.3 and Supplemental Figure 3.5A-L).  
 In efforts to further examine collagen organization, a (flpHypGly)7 collagen 
mimetic peptide (CMP) conjugated to a cyanine 5 (Cy5) dye was used to stain sections of 
control and Hox11ROSACreERT2 conditional mutant bone. The Cy5CMP mimics the proline-
hydroxyproline-glycine amino acid triplet motif that is prevalent in collagen (constituting 
~10.5% of the protein sequence) and selectively anneals to disrupted sites in collagen153.  
Control bone sections were virtually devoid of any staining, as expected for a highly 
organized collagen matrix while conditional mutant bones displayed strong binding of 
throughout the regions of abnormal matrix (Figure 3.4G-J). Use of a compositional 
isomer (Cy5CI) that differs in sequence from Cy5CMP did not stain either control or mutant 
bone sections as expected (Supplemental Figure 3.5M, N)153. 
As osteoclasts have a strong influence on bone integrity, we examined osteoclast 
number and localization in the controls and conditional mutants. Tartarate resistant acid 
phosphatase (TRAP) is a metalophosphoesterase that participates in osteoclast-mediated 
bone resorption and is used to visualize osteoclasts154. In control bones, TRAP staining is 
concentrated along the endosteal bone surface. In the Hox11ROSACreERT2 conditional mutant 
bones, TRAP staining is also observed on the endosteal bone surface, however there are 
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also trails of TRAP stain present within the abnormal cortex of the conditional mutant 
bones (Figure 3.4K, L). A higher magnification of the osteoclasts on the control bone 
surface demonstrate that the osteoclasts and TRAP stain localized at the surface of the 
bone as expected. High magnification of the conditional mutant bone shows TRAP 
enzyme within the abnormal bone matrix in addition to the bone surface. However, there 
were no cells associated with the TRAP stain, leading to the conclusion that the abnormal 
matrix is allowing diffusion of the enzyme into the matrix (Supplemental Figure 3.6A-
D). While TRAP staining is broader in the conditional mutant bones, quantification of the 
bone surface osteoclasts showed no significant difference in the number of osteoclasts in 
the control and conditional mutants (Figure 3.4M). The disorganized collagen matrix in 
conjunction with the diffusion of TRAP staining in the cortical matrices indicates the 
presence of a defective matrix in the Hox11ROSACreERT2 conditional mutant bone. 
 
Abnormal bony matrix arises from Hox11-lineage cells 
  We next used the Hoxa11-CreERT2 allele to simultaneously conditionally delete 
the function of Hox11 and lineage-trace the Hox-expressing cells by including a ROSA26-
LSL-tdTomato allele. Females with the genotype Hoxa11eGFP/+;Hoxd11loxP/loxP were 
mated to males with the genotype Hoxa11CreERT2/+;Hoxd11loxP/loxP;ROSALSL-tdTom/LSL-tdTom 
to generate embryos with the genotype Hoxa11CreERT2/eGFP;Hoxd11loxP/loxP;ROSALSL-tdTom/+ 
(referred to as Hox11Hoxa11CreERT2 conditional mutants). Conditional mutant animals, 
along with their corresponding controls, were given tamoxifen chow for 3 weeks and 
chased for 2 months following the initiation of deletion and the contribution of the 
Hox11-expressing cells to bone was observed. The extent of lineage contribution 
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Figure 3.3. Deletion of Hox11 function at adult stages result in the regional 
disruption in cortical bone homeostasis. Hox11 conditional mutants with the ROSA-
CreERT2 (genotype indicated) allele along with control animals were fed on tamoxifen 
chow at 8-10 weeks of age for 3 weeks to induce deletion of Hox11 function and chased 
for 2 months (4-months of age), 4 months (6-months of age), and 10 months (1 year of 
age). (A) Tail samples from all animals collected were analyzed via PCR to assess 
		 78	
recombination. A robust 300bp band in the conditional mutants demonstrate strong 
recombination. (B) qRT-PCR of Hoxa11eGFP-expressing zeugopod skeletal cells of the 
conditional mutants show robust deletion of Hoxd11 in the conditional mutants. Data is 
presented relative to mouse GAPDH using the DDCt method. ND, none detected. Error is 
represented as mean ± SEM. (C-H) H&E stains of paraffin bone sections (ulna) of 
control and Hox11ROSACreERT2conditional mutant animals. Dashed line demarcates the 
border between lamellar (above) and abnormal (below) bone. Inset in (E) and (F) show 
close-up of osteocyte to highlight distinct morphology. Brackets demarcate the abnormal 
matrix. (J, K) H&E stains of bones from the humerus of control (J) and Hox11 
conditional mutant (K) show no differences in morphology at 1-year of age. (I) 
Quantification of cells embedded within the abnormal matrix at 4-months, 6-months, and 
1-year of age show a significant increase in cell number in Hox11ROSACreERT2 conditional 
mutant bone. Error is represented as mean ± SEM. Statistics by Student’s t test; *p < 
0.05. All images, PO = periosteum, CB = cortical bone, BM = bone marrow. Scale bar in 
all images: 100µm.  
 
observed between the control and Hox11Hoxa11CreERT2 conditional mutant bones is similar 
with no obvious differences in the cortical thickness of lineage-marked cells embedded in 
the bone matrix (Figure 5A, B). Control bones displayed a well-organized bone structure 
with lineage-labeled osteocytes embedded in the lamellar bone (Figure 5A). In contrast, 
the region with Hox11-lineage mutant cells precisely correlate with the abnormal matrix 
region clearly distinguishable in brightfield images (Figure 5B, bracket). These results 
strongly support that the abnormal matrix formed in the conditional mutant bones arise 
from the descendants of the cells that have lost Hox11 function. 
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Figure 3.4. Woven bone region in the Hox11 conditional mutant bones have a 
disorganized collagen matrix. Hox11 conditional mutants with the ROSA-CreERT2 
(genotype indicated) allele along with control animals were fed on tamoxifen chow at 8-
10 weeks of age for 3 weeks to induce deletion and chased for 4 months (6-months of 
age). (A, B) H&E stains of paraffin processed bone sections of control and 
Hox11ROSACreERT2 conditional mutant animals. (C, D) Brightfield images of picrosirius 
red stain of consecutive bone sections from B and C. (E, F) Polarized light images of 
picrosirius red stain of bone sections from D and E. (G, H) H&E stains of paraffin 
processed bone sections of control and Hox11ROSACreERT2 conditional mutant animals. (I, 
J) Consecutive bone sections from H and I stained with the collagen mimetic protein 
probe (red). White dashed line marks border of cortical bone. (K, L) Control (K) and 
Hox11ROSACreERT2 conditional mutant (L) bone sections stained with TRAP. Note the 
distinct distribution of TRAP stain in conditional mutant. Scale bar: 200µm. (M) 
Quantification of osteoclast number on bone surface using the Bioquant Osteo software. 
Statistics by Student’s t test; *p < 0.05. Error is represented as mean ± SEM. All images 
are from the ulna, PO = periosteum, CB = cortical bone, BM = bone marrow. Yellow 
dashed line demarcates border between lamellar (above) and abnormal (below) bone. 
Scale bar in all images: 100µm.  
 
Hox11 conditional mutant osteoblasts exhibit deficient differentiation 
In vivo, mature osteoblasts are primarily defined by their morphology as definitive 
cellular markers are currently lacking. They appear on the bone surface as large cuboidal 
cells with a round nucleus located in the cell away from the bone surface155. As Hox11 is 
not expressed in fully mature cells, we identified bone surface osteoblasts as 
Hoxa11eGFP-negative, Hoxa11-lineage-positive (red) cells. In control bones, we 
observed mature osteoblasts that present the classical, cuboidal morphology and nuclear 
localization (Figure 3.5C-C’’, arrowhead). Noticeably, bone surface cells that retained 
Hoxa11eGFP-expression displayed a rounder morphology but were not cuboidal in 
shape, nor was the localization of the nucleus polarized away from the bone surface, 
indicating that these cells may be in the process of beginning to differentiate. All bone 
surface cells in the conditional mutant bones, in contrast, appeared flatter compared to 
those in controls with no nuclear migration away from bone surface (Figure 3.5C-D’’, 
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arrowhead). 
During normal osteoblast differentiation, Runx2 marks cells that have committed 
to the osteoblast lineage (pre-osteoblasts). Maturation of osteoblasts leads to the 
expression of osteopontin (Opn) at relatively early stages of osteoblastic differentiation, 
and osteocalcin (Ocn) is expressed in fully mature osteoblasts coincident with their 
assuming the characteristic cuboidal shape156. To determine whether Hox mutant cells 
initiate differentiation, Runx2 expression was examined. Runx2 expression was observed 
in both control and mutant bones on the cell surface of the endosteal bone (Figure 3.5E, 
F). However, Hox11Hoxa11CreERT2 conditional mutant bones were almost completely 
devoid of both Opn and Ocn staining whereas, in contrast, expression of both markers 
lined the endosteal surface of the control bones (Figure 3.5G-J). These data provide 
strong evidence that differentiation towards the osteoblast lineages is able to initiate in 
Hox11 mutant skeletal stem cells, but terminal differentiation of osteoblasts is disrupted. 
 
Osteocyte differentiation and morphology is disrupted with loss of Hox11 function in 
bone 
 Osteocytes are terminally differentiated osteoblasts that become embedded within 
the bone matrix and are the primary mechanosensory cells of the bone with important 
roles in bone homeostasis65,157. Long dendritic processes are characteristic of osteocytes; 
these are used to connect neighboring osteocytes to each other as well as to bone surface 
cells, including the cell surface osteoblasts and osteoclasts63,64. To examine whether 
maturation of osteocytes was also affected by the loss of Hox11 function, we used a silver 
nitrate stain to visualize the dendritic processes. We observed a complete absence of the 
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formation of dendrites and a complete absence of the normal canalicular network in 
Hox11 conditional mutant osteocytes present within abnormal bone matrix regions 
(Figure 3.6B-E).  
Mature osteocytes produce and secrete the protein sclerostin, encoded by the SOST 
gene. Following a 2-month chase using our Hoxa11-CreERT2 allele, Hox11-lineage 
marked, osteoycyte-like cells are found embedded in both the control and 
Hox11Hoxa11CreERT2 conditional mutant bones (Figure 3.6G, H). While virtually all of the 
lineage-marked osteocytes in the control bone express SOST, most Hox11Hoxa11CreERT2 
conditional mutant lineage-marked osteocytes failed to express SOST (Figure 3.6I-M), 
demonstrating a requirement for Hox function in proper osteocyte differentiation.  
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Figure 3.5. Hox11 conditional mutant cells directly give rise to the woven bone. 
Hox11 conditional mutants with the Hoxa11-CreERT2 allele (genotype indicated) along 
with control animals were fed on tamoxifen chow for 3 weeks starting at 8-10 weeks of 
age and collected following a 2-month chase (4-months of age). (A) Brightfield image of 
a bone section from a control animal overlaid with Hox11-lineage marked cells (red) 
shows contribution to osteocytes. (B) Brightfield image of bone section from a 
Hox11Hoxa11CreERT2 conditional mutant overlaid with Hox11-lineage positive cells (red) 
shows contribution to abnormal bone matrix. (C-D’’) Hoxa11eGFP (green) and DAPI 
(blue) in C and D, Hoxa11-lineage marked cells (red) and DAPI (blue) in C’ and D’, and 
merged images in C’’ and D’’. Control (C-C’’) and Hox11Hoxa11CreERT2 conditional mutant 
(D-D’’) bone sections show Hoxa11-lineage marked (red), non-Hoxa11eGFP (green) 
endosteal surface osteoblasts (yellow arrowhead). Notice stark difference in morphology. 
(E, F) Control (E) and Hox11Hoxa11CreERT2 conditional mutant (F) bone stained with 
RUNX2 (magenta). DAPI: gray. (G, H) Control (G) and Hox11Hoxa11CreERT2 conditional 
mutant (H) bone stained with osteopontin (OPN, green). (I, J) Control (I) and 
Hox11Hoxa11CreERT2 conditional mutant (J) bone sections stained with osteocalcin (OCN, 
green). All images are from the ulna, DAPI: blue (unless noted otherwise), Hox11-
lineage marked cells: red, endo = endosteum, CB = cortical bone, and white dashed line 
demarcates the endosteal surface. Scale bars in all images: 50µm. 
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Figure 3.6. Hox11 conditional mutant osteocytes fail to form dendrites or express 
SOST. Hox11 conditional mutants with the ROSA-CreERT2 (genotype indicated) allele 
along with control animals were fed on tamoxifen chow at 8-10 weeks of age for 3 weeks 
to induce deletion of Hox11 function and chased for 2 months (4-months of age), 4 
months (6-months of age), and 10 months (1 year of age) for panels C-E. (A-C) Control 
(left panels) and Hox11ROSACreERT2 conditional mutants (right panels) were treated with 
silver nitrate. Green dashed lines demarcate the lamellar (above) and abnormal (below) 
bone. Brackets outline mark abnormal bone matrix. (D) High magnification of osteocytes 
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from the white-boxed area. Hox11 conditional mutants with the Hoxa11-CreERT2 allele 
(genotype indicated) alone with control animals were fed on tamoxifen chow for 3 weeks 
starting at 8-10 weeks of age and collected following a 2-month chase (4-months of age) 
for panels G-O. (E, F) Control (E) and Hox11Hoxa11CreERT2 conditional mutant (F)  bone 
sections showing Hox11-lineage marked cells (red) that contributed to osteocytes. (G, H) 
Control (G) and Hox11Hoxa11CreERT2 conditional mutant (H) bone sections stained with 
SOST (green). (I, J) Merged images of E, G in (I) or F, H in (J) showing overlap or the 
lack thereof of Hox11-lineage marked cells (red) and SOST (green). (K, L) Close up of 
osteocytes in white-boxed region in K and L. (M) Quantification of Hox11-lineage 
marked cells (red) that also express SOST (green). Error is represented as mean ± 
SEM. Statistics by Student’s t test; *p < 0.05. All images are from the ulna, DAPI: gray, 
PO = periosteum, CB = cortical bone, BM = bone marrow. Scale bar: 25µm (B-D), 10µm 
(E), 100µm (G-L), 10µm (M-N).  
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Discussion 
Woven bone is made primarily during the rapid bone growth of embryogenesis or 
following bone injury (e.g. fracture)158,159. In both cases, the initial woven bone matrix is 
remodeled and replaced by lamellar bone through a process that is not fully understood. 
The accumulation of woven bone with no signs of lamellar remodeling in our Hox11 
conditional mutants demonstrate that proper skeletal matrix formation during 
homeostasis is dependent on Hox function. All of the evidence presented in this study 
supports defective differentiation of osteolineage cells with the loss of Hox11 function. 
Osteoblasts originate from skeletal stem cells and previous work from our lab as well as 
results presented here unequivocally demonstrate that Hox11-expressing skeletal stem 
cells give rise to osteoblasts. As Hox11 expression is restricted to the stem cell population 
and is not observed in differentiated skeletal cells, we conclude that Hox proteins 
function in the stem cells at early stages of differentiation.  
The results from our conditional Hox11 loss-of-function model correlates with 
earlier investigations into embryonic null mutants. When Hoxa11/Hoxd11 mutants were 
examined at E14.5, the stage at which when overt osteoblasts are beginning to 
differentiate in the zeugopod skeletal anlage, Runx2 expression was observed in the 
perichondrial region160. Consistent with our observation in the Hox11 conditional 
mutants, subsequent maturation of osteoblasts are clearly perturbed in the 
Hoxa11/Hoxd11 mutants as their zeugopod skeletal elements do not develop further 
resulting in two grossly stunted elements (Figure 3.2F and 20). Intriguingly, these results 
are consistent with a similar function for Hox in the skeleton throughout life, however, 
this would require further investigation to conclude.  
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 The abnormal collagen matrix secreted by the abnormally-differentiated 
osteoblasts in the adult conditional mutants may have a compounding role in the skeletal 
phenotype. Mice that harbor a mutation in Col1a1 that produces type 1 collagen 
molecules resistant to cleavage by collagenase manifest a haphazard endosteal bone 
growth reminiscent of the Hox11 conditional mutant bones161. The binding of CMP to 
collagen strands in our Hox conditional mutant bone supports abnormal processing of 
collagen. The similarity in bone phenotypes suggest that the abnormal collagen matrix is 
a critical manifestation of the Hox conditional loss-of-function phenotype. It is possible 
that collagen helices produced by Hox mutant osteoblasts do not undergo the proper 
processing required for the normal organization to lamellar bone or there may be an 
absence of enzymes or other molecules necessary for remodeling the collagen matrix. 
Further interrogation is required to understand the molecular mechanisms that lead to this 
defect.   
Our results test a hypothesis put forward by Bradaschia-Correa, et al. that states 
Hox expression in periosteal stem/progenitor cells determines the cell fate of those 
stem/progenitor cells in adult animals125. In this report, the authors associated Hox-
expressing periosteal stem/progenitor cells with more primitive, stem cell-like gene 
ontology terms and exhibited more accessible chromatin at transcriptional start sites125. 
Recent work from our laboratory demonstrating that Hox expression is associated with 
skeletal stem cells are consistent with their findings86,147. Results presented here 
genetically support their hypothesis that Hox genes confer differentiation cues to these 
stem cells throughout life. Bradaschia-Correa, et al. also hypothesize that Hox function 
may be required for maintenance of the stem cell population125. However, previously we 
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have shown that Hox11-expressing skeletal stem cells are maintained in Hox11 
compound mutants at relatively comparable numbers compared to controls86. We more 
directly test complete loss-of-function in this study and we find Hoxa11eGFP-positive 
conditional mutant cells are still present 10 months after deletion of Hox function. 
Furthermore, the progressive nature of the phenotype observed in our Hox11 conditional 
mutants support maintenance of the Hox11-expressing skeletal stem population for 
continued (abnormal) contribution to the osteolineage. Cumulatively, these data provide 
compelling evidence that maintenance of the skeletal stem cell pool is independent of 
Hox function.  
Herein, we show that Hox gene function in the skeleton is not restricted to 
development and that Hox genes play a crucial, functional role in adult bone homeostasis. 
Adult Hox11 loss-of-function leads to a replacement of the lamellar cortical bone with an 
abnormal woven bone-like matrix. We have demonstrated strong evidence that this 
woven bone matrix is directly produced by the Hox11 conditional mutant cells and the 
woven bone matrix is associated with the deficient differentiation and maturation of 
osteoblasts resulting from the loss-of-function of Hox11 in the zeugopod skeletal stem 
cells.  
Whether other Hox paralogous genes function to maintain the adult skeleton 
remains an intriguing question for future studies. Previous studies from our laboratory 
showing the preservation of region-specific Hox expression specifically within 
progenitor-enriched stem cell populations at adult stages support this likelihood86. While 
embryonic loss-of-function has clearly established that Hox genes impart region-specific 
function that differentially controls skeletal patterning and morphology, results from this 
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study raise the question of whether differential Hox gene function continues to be 
conveyed in a region-specific manner or whether all Hox function is similar once the 
skeleton has been established. 
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Supplemental Information 
 
Supplemental Figure 3.1. Adult Hox11-expressing skeletal stem cells continuously 
contribute to endosteal osteoblasts. Animals harboring the Hoxa11-CreERT2 allele 
(genotype indicated) were fed on tamoxifen chow for 3 weeks starting at 8-10 weeks of 
age and collected after a 6-month chase at 8-months of age. (A, B) High magnification 
images of Hoxa11-lineage marked osteoblasts (red) co-expressing Osx (white) on the 
endosteal surface. White dashed line demarcates the endosteal surface. DAPI: blue. All 
images are from the ulna, endo = endosteum, CB = cortical bone. Scale bar, 25µm. 
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Supplemental Figure 3.2. CRISPR/Cas9 generation of the Hoxd11 conditional allele. 
(A) PCR genotyping of founder (F0) animals for insertion of the 5’ loxP site. Animals 
#377, 387, and 394 were sequence verified and male F1 animals were used as stud males 
for second round of targeting. (B) PCR genotyping of F0 animals for insertion at the 5’ 
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loxP (top panel) and 3’ loxP (bottom panel). Animals # 742, 743, 745, 750, 763 and 767 
were heterozygous for 5’ loxP and sequence verified to harbor correctly targeted 3’ loxP. 
Animals #742 and 745 were found to be chimeric. Animal #763 contained the loxP sites 
in trans. Animals # 743, 750 and 767 contained the loxP sites in cis and #743 was 
selected to be the final founder. (C) 8-week old adult with the genotype ROSACreERT2/LSL-
tdTomato; Hoxd11loxP/loxP without tamoxifen administration shows minimal recombination 
visualized by ROSA-lineage marked cells (red). DAPI: blue. Scale bar: 200µm. (D) PCR 
analysis shows that the minimal recombination seen in the zeugopod bones do not result 
in detectable recombined bands (right panel) and robust control band (left panel). All 
three samples are from Hox11ROSACreERT2. (E) Equally strong detection of the recombined 
PCR band between zeugopod skeleton and tail sample taken from Hox11ROSACreERT2 
conditional mutant. 
 
 
 
Supplemental Figure 3.3. Hox11-expressing skeletal stem cells are maintained in the 
Hox11 conditional mutants. Animals harboring the Hoxa11-CreERT2 allele (genotype 
indicated) were fed on tamoxifen chow for 3 weeks starting at 8-10 weeks of age and 
collected after a 10-month chase at 1-year of age. (A, B) Hox11eGFP-expressing skeletal 
stem cells (green) are present in the expected locations at 1-year of age in both the control 
(A) and Hox11 conditional mutants (B). All images are from the ulna, PO = periosteum, 
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CB = cortical bone, endo = endosteum, BM = bone marrow. DAPI: blue. Scale bar, 
75µm.  
 
 
Supplemental Figure 3.4. Long-term deletion of Hox11 function at adult stages do 
not lead to noticeable gross morphological differences. Hox11 conditional mutants 
with the ROSA-CreERT2 (genotype indicated) allele along with control animals were fed 
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on tamoxifen chow at 8-10 weeks of age for 3 weeks to induce deletion of Hox11 
function and chased for 2 months (4-months of age), 4 months (6-months of age), and 10 
months (1 year of age). (A) Top panel: 3D rendering from microCT scans of the 
zeugopod skeleton (radius/ulna) from control and Hox11ROSACreERT2 conditional mutants. 
Bottom panel: Cross section of the zeugopod skeleton through the distal end at 10% of 
the entire length of the ulna. (B) Table outlining the morphological measurements 
generated from microCT scans. Statistics by Student’s t test; *p < 0.05. 
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Supplemental Figure 3.5. Adult conditional deletion of Hox11 function lead 
abnormal matrix. Hox11 conditional mutants with the ROSA-CreERT2 (genotype 
indicated) allele along with control animals were fed on tamoxifen chow at 8-10 weeks of 
age for 3 weeks to induce deletion of Hox11 function and chased for 2 months (4-months 
of age) and 10 months (1 year of age). (A-D) H&E stains of control (A, C) and 
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Hox11ROSACreERT2 conditional mutant (B, D) at 4-months and 1-year of age. (E-H) 
Brightfield images of picrosirius red stain of consecutive bone sections from A-C. (I-L) 
Polarized light images of picrosirius red stain of bone sections from E-H. Arrows (yellow 
(B), black (F) white (J)) highlight the abnormal matrix in 4-month old conditional mutant 
bone.(M, N) Bone sections from control (M) and Hox11ROSACreERT2 conditional mutant 
(4-month chase) were stained with Cy5CI. Both bone sections do not show staining. White 
dashed line marks border of cortical bone. All images are from the ulna, PO = 
periosteum, CB = cortical bone, BM = bone marrow. Scale bar in all images: 100µm.  
 
 
Supplemental Figure 3.6. Distribution of TRAP staining, but not number of 
osteoclasts is distinct in Hox11 conditional mutant bones. Hox11 conditional mutants 
with the ROSA-CreERT2 (genotype indicated) allele along with control animals were fed 
on tamoxifen chow at 8-10 weeks of age for 3 weeks to induce deletion of Hox11 
function and chased for 4 months (6-months of age). (A-B) Higher magnification of 
osteoclasts to show apparent TRAP stain leakage into cortical bone matrix.  Yellow 
dashed line demarcates the endosteal bone surface. TRAP enzyme leaked into the bone 
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matrix in mutants (blue arrow). Scale bar: 25µm (C, D) TRAP stain with hematoxylin for 
visualization of nuclei. No cells were associated with TRAP stain in cortical bone (yellow 
arrow). Yellow dashed line demarcates the endosteal bone surface. Scale bar: 25µm. All 
images are from the ulna, PO = periosteum, CB = cortical bone, BM = bone marrow. 
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Materials and methods 
Mice 
 All mice were maintained in a C57BL/6 background. Both male and female mice  
 
were used for all experiments. The mouse models Hoxa11-eGFP133 and Hoxa11-
CreERT285 have been previously described. The ROSA26-CAG-loxP-stop-loxP-
tdTomato (JAX stock #007909) and ROSA26-CreERT2 (JAX stock #008463) were 
purchased from Jackson Laboratory. The Hoxd11-floxed animals were obtained by 
breeding founder Hoxd11-floxed animals to wildtype C57BL/6 animals for 5 generations 
followed by breeding Hoxd11-loxP heterozygotes to each other to produce Hoxd11-
floxed animals. These animals were periodically bred to wildtype C57BL/6 animals to 
avoid genetic drift. The Col2.3-GFP mice were kindly provided by Dr. Noriaki Ono then 
bred with our Hoxa11 and Hoxd11 mice to generate animals of appropriate genotype. All 
animal experiments described in this article were reviewed and approved by the 
University of Michigan’s Committee on Use and Care of Animals, protocol PRO0000-
8674 (Wellik).  
 
Generation of Hoxd11 conditional allele 
The Hoxd11 conditional allele was generated in two injection rounds, targeting 
each loxP site sequentially. Two guide sequences were targeted to regions of low 
conservation within the  Hoxd11 intron (5’, upstream) and downstream of the 3’ 
untranslated region (UTR) (3’, downstream) flanking  exon 2 of the Hoxd11 locus were 
cloned into the pT7-Guide Vector (Blue Heron Biotech, LLC). The guide sequence, 
approximate locations, and corresponding PAM sequences are indicated in Figure 2A. 
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Donor oligos contained 60bp of flanking homology sequence, the loxP sequence (bold 
letters), and a unique restriction site (EcoRI [5’ loxP] or NheI [3’ loxP], capital letters) 
for optional use in confirming accurate targeting. Single stranded DNA oligos were 
purchased from Integrated DNA Technologies. 
5’ loxP donor oligo sequence (from 5’ to 3’): 
gttgatgagtgggaacacgagagcctcctgcctttcagggagagggtaagtgatctgcc GAATTC 
ataacttcgtataatgtatgctatacgaagttat gcactggacttaaccccaacctctggctg 
gcgctcagctcggagttgagcagatgctcctg 
3’ loxP donor oligo sequence (from 5’ to 3’): 
tctgattagacttacatcatctctagcatttgaaagcaatttgccaccctgctaaataa GCTAGC 
ataacttcgtataatgtatgctatacgaagttat acgctggcactttataaaatatagaa  
caaagtaaaatatagttatattgtttcgtaaac 
The guide RNAs were in vitro transcribed from the pT7-Guide Vector using the 
MEGAshortscript T7 kit (Life Technologies, AM1354) and products were subsequently 
purified using the MEGAclear kit (Life Technologies, AM1908). Using the pT7-Cas9-
Nuclease vector (gift from Dr. Moises Mallo), the Cas9 mRNA was in vitro transcribed  
using the mMESSAGE mMACHINE T7 ULTRA kit (Life Technologies, AMB13455) 
and purified using the MEGAclear kit (Life Technologies, AM1908).  
 Zygote injections were performed as previously described with minor 
modifications145. C57BL/6 and SJL mixed background female mice were superovulated 
and mated with C57Bl/6 and SJL mixed background male mice and one-cell stage 
embryos were collected for microinjection. CRISPR reagents were microinjected at the 
following concentrations: Cas9 mRNA (100ng/μL), sgRNA (50ng/μL), and DNA oligo 
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(50ng/µL). Injected zygotes were transferred into pseudopregnant females and resulting 
progeny were initially screened for potential recombination events via PCR. 
 The intronic loxP site was targeted first. PCR primers, 5’- 
ATGAGTGGGAACACGAGAGC-3’ and 5’- AGGCTGGCACTGAGATAGGA-3’ were 
used to screen for loxP insertion. PCR products were cloned for sequencing using the 
TOPO TA cloning kit (Thermo Fisher, 450071). Male mice validated to contain correctly 
targeted loxP sequence from the first round of injection were used as stud males for 
targeting of the 3’ region of Hoxd11 exon2. PCR primers 5’- 
AAAGCAATTTGCCACCCTGC-3’ and 5’- ACAGGTAAACCAATGCCCAGA-3’ 
were used to screen for loxP insertion at the 3’ region of the Hoxd11 exon2. Targeting 
was verified by PCR and sequencing as above. Animals (male or female) confirmed to 
contain two correctly targeted loxP sites were mated to wild-type Bl6 animals and 
genotyping analyses of the resulting progeny using the PCR primers indicated above 
were used to screen for germline transmission and the presence of both loxP sites in cis 
along the chromosome.  
 
Tamoxifen treatment 
 Mice were fed on tamoxifen chow (Envigo, TD. 130860) at 8-10 weeks of age for 
a duration of 3 weeks. Based on approximate daily food intake of 4g/mouse162 and body 
weight of 20-25g, mice consumed a concentration of 40mg/kg of tamoxifen per day. The 
chow was replaced weekly. Both control and conditional mutants were fed on tamoxifen 
chow.  
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Bone tissue preparations 
Mice were euthanized and both forelimb zeugopod skeletons were collected by 
dissecting off the soft tissue,  taking care not to disturb the periosteum. All bones were 
then fixed shaking in 4% paraformaldehyde (PFA) for 2 days at 4°C then scanned for 
microCT if required. Specimens for frozen sections were decalcified in 14% EDTA for 7 
days and equilibrated in 30% sucrose overnight prior to embedding in OCT media. 
Cryosections were collected at 10-12μm using the Kawamoto tape method146. Specimens 
for paraffin sections were decalcified in 14% EDTA for 7 days and dehydrated in 70% 
ethanol prior to overnight paraffin processing. Paraffin sections were collected at 5μm.  
 
Histology, immunohistochemimstry, histomorphometry, microCT, and quantification 
 As Hox11 expression within the zeugopod skeleton is higher in the ulna compared 
to the radius, all detailed analyses were carried out in the ulnar bone. Histological stains 
were performed using standard methods163. Paraffin sections were de-paraffinized and 
rehydrated by incubating in xylene followed by a series of washes in decreasing ethanol 
content (100%, 95%, 70%, ddH2O). H&E stains were processed as previously 
reported163. Tartrate-resistant acidic phosphatase (TRAP) staining (Sigma-Aldrich, 387A-
1KT) and picrosirius red stain (Abcam, ab150681) were performed according to 
manufacturer’s protocol. For the visualization of the osteocyte lacuna-canilicular 
network, the bone sections were processed as previously reported with minor 
modifications164. All histological images were acquired on an Eclipse E800 microscope 
(Nikon).  
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 For immunostaining, cryosections were blocked with 5% donkey serum and 
incubated with primary antibodies overnight at 4°C against Osterix (Abcam, ab22552, 1: 
300), Osteopontin (R&D Systems, AF808, 1:200), and Osteocalcin (antibody no longer 
commercially available, RayBiotech, DS-PB-01521, 1:200). Secondary antibodies were 
incubated at room temperature for 1h: donkey-anti-rabbit-Alexa Fluor 647 (Thermo 
Fisher, A31573, 1:500), donkey-anti-goat-Alexa Fluor 488 (Thermo Fisher, A11055, 
1:500). SOST was visualized using a modified signal amplification protocol. Sections 
were incubated in SOST (R&D Systems, AF1589, 1:100) overnight at 4°C followed by 
donkey-anti-goat-biotin secondary (Jackson ImmunoResearch, 705-067-003, 1:400). The 
biotinylated secondary was detected using the Vectastain Elite ABC kit (Vector 
Laboratories, PK-6100) and signal was amplified by Alexa Fluor 488 Tyramide reagent 
(Thermo Fisher, B40853). Endogenous Hoxa11eGFP fluorescence was quenched after 
the decalcification process and was visualized using chicken-anti-GFP (Abcam, ab13970, 
1:1000) and donkey-anti- chicken-Alexa Fluor 488 (Invitrogen, A11039, 1:500). All 
fluorescent images were acquired on a Leica Upright SP5x 2-photon confocal 
microscope. Confocal z-stacks were captured through entire sections at a thickness of 1-
2µm and images were stacked using Photoshop. Large images were stitched (when 
necessary) using Photoshop. 
 Fluorophore-labeled CMP and CI were synthesized as described previously153. 
Briefly, Cy5CMP has the sequence: Cy5-Gly-(SerGly)2-(flpHypGly)7-OH, where flp 
refers to (2S,4S)-4-fluoroproline and Hyp refers to (2S,4R)-4-hydroxyproline. Cy5CI has 
the sequence: Cy5-Gly-(SerGly)2-(HypflypGly)7-OH. Paraffin bone sections were 
stained in the dark for 1 hour at room temperature, then washed with 1X PBS.  
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Quantification of osteocytes and tdTomato+/SOST+ cells were obtained by taking 
three 40X images at the distal, medial, and proximal region along the ulna and the cells 
were manually quantified using ImageJ. An average among the three regions was 
calculated for each animal. At least 5 animals from each indicated genotype were 
examined.  Quantification of osteoclasts was performed using the Bioquant Osteo 
software V17.2.6 (Bioquant Image Analysis Corp., Nashville, TN) according to standard 
procedures165. 
 MicroCT analyses were performed using a lab microCT (Skyscan 1176; Bruker, 
Billerica, MA, USA) at 9 µm isotropic resolution utilizing a 0.3° rotation step, 0.5 mm 
aluminum filter, and 2 frame averaging. Data from the microCT scans were processed 
and analyzed using MicroView (v2.1.2 Advanced Bone Application; GE Healthcare 
Preclinical Imaging).  
 
Skeletal Preparations 
 E17.5 embryos were skinned and eviscerated, fixed in 100% ethanol overnight 
then in acetone overnight. Specimens were stained with alcian blue in a solution 
containing 15mg alcian blue (Alcian blue 8GX, Sigma, A5268), 80ml of 95% ethanol and 
20ml of glacial acetic acid up to two days. The skeletons were rinsed in 100% ethanol 
overnight and cleared in 2% KOH for 3 hrs. The specimens were transferred into alizarin 
red staining solution with 50mg/L alizarin red (Alizarin Red S, Sigma, A5533) in 2% 
KOH for 3-5 hrs. The tissue was then cleared in 1% KOH with 20% glycerol and 
transferred through an increasing glycerol series (20%, 50%, 80%), finally into 100% for 
long-term storage.  
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qRT-PCR for Hoxd11 expression 
 To analyze deletion of Hoxd11 following recombination, control and Hox11 
conditional mutant were collected after a 1-month chase. The soft tissue from both 
forelimb zeugopod skeletons were removed and the bone marrow was flushed from both 
the radius and ulna into 1ml of digestion buffer (2mg/ml of collagenase type IV (Thermo 
Scientific, 17104-019) and 3mg/ml of dispase II (Thermo Scientific, 17105-041)	 in 1X 
PBS) using a 30G needle. The bones were subsequently minced with a razor in a petri 
dish under a tissue culture hood and the resulting pulp was transferred into digestion 
buffer with the flushed bone marrow. Three digestion steps were carried out at 37°C with 
periodic agitation to obtain a single cell suspension. After each period of digestion, cells 
in suspension were collected into cell culture media containing DMEM with 4.5 g/L D-
glucose (Gibco), 1X Glutamax (Gibco), 1mM sodium pyruvate, 15% fetal bovine serum 
(FBS), 100 mg/mL streptomycin, and 100 U/mL penicillin. Red blood cells were lysed on 
ice at a final concentration of 0.5X. The cells were then strained through a 100µM cell 
strainer and plated. The cells were expanded, passaged twice, then subsequently sorted by 
a MA900 (Sony) cell sorter to obtain Hoxa11eGFP-expressing cells. RNA was extracted 
using the Qiagen RNeasy micro kit (Qiagen, 74004) and cDNA was synthesized using 
Superscript™ (Thermo Fisher, 11904018). Hoxd11 expression was measured relative to 
GAPDH.	qPCR was performed with the following primer set using Roche PowerUp™ 
SYBR™ Green Mastermix: Hoxd11R AGTGAGGTTGAGCATCCGAG, Hoxd11F 
ACA CCAAGTACCAGATCCGC. DCt values were calculated relative to GAPDH. 
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CHAPTER IV 
Conclusion 
Summary of significant findings 
 The most significant finding in this work is the demonstration of the continued 
function of Hox genes beyond embryogenesis. Much previous work has focused on the role 
of Hox genes during skeletal development and their requirement after the skeleton is 
established was largely undetermined. This study, for the first time, show clear genetic and 
functional data regarding the continuing function of Hox genes in skeletal stem cells 
governing their differentiation towards the osteolineage. Adult conditional loss of Hox11 
function leads to an accumulation of a woven bone-like matrix that progressively replaces 
normal lamellar bone. This primarily stems from the inability of Hox11 conditional mutant 
osteoblasts to fully differentiate and mature to produce a normal bone matrix. Lineage 
analysis clearly demonstrates that the cells downstream of the Hox11-expressing skeletal 
stem cells that lost Hox function constitute the abnormal bone matrix. Further, the 
osteocyte-like cells embedded in the abnormal matrix completely lack dendrites failing to 
establish a lacuna-canilicular network and exhibit maturation deficiencies.  
 The conditional deletion of Hox function in my study addresses the drawbacks of 
many models used to determine the role of Hox genes beyond their classic embryonic role. 
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Using engineered overexpression from retroviral vectors and transgenic knockout or 
knock-in mouse models it has been shown that abnormal Hox expression results in 
improper differentiation of hematopoietic stem cells leading to an imbalance of 
downstream blood lineages166–168. Further, deregulation of Hox genes have also been linked 
to the predisposition or progression of many different malignancies66,70,169,170. While 
important insight has been shed through these studies, an important fact to keep in mind is 
that most of these studies have been conducted in vitro using freshly isolated cells or 
established cells lines. It is known, especially in the context of stem cells, that their in vitro 
capacity does not faithfully reflect their in vivo behavior. Moreover, the vast majority of 
the studies use null mutants that harbor non-functional Hox genes from development. As 
mentioned previously, this obfuscates the phenotypes observed at later stages as it is 
challenging to distinguish which defects can be attributed to the loss of Hox function and 
which are secondary to the already abnormal physiology that manifest during 
embryogenesis. Therefore, using a conditional deletion allele that allows for temporal 
deletion of Hox function, I was able to control for normal development and growth 
subsequently deleting Hox11 function at adult stages to interrogate the specific role Hox 
genes play during adult skeletal homeostasis.  
 Results from my work show that the conditional loss of Hox11 leads to the 
perturbation of the osteolineage differentiation revealing definitive evidence for a 
continuing role for Hox genes in the adult skeleton. However, the specific molecular 
mechanism of how Hox genes exert their function is still unclear. It is critical to reiterate 
that Hox genes encode transcription factors and are expected to exert their function in a 
cell autonomous manner at the transcriptional level.  One of the main functions of 
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osteoblasts is the secretion of a collagen matrix that subsequently become mineralized 
constituting the hard bony matrix of the skeleton. Therefore, a possible mechanism of 
Hox11 function may involve the proper transcription of collagen chains, the transcription 
of enzymes involved in the post-translational modification or transcription of proteins 
involved in subsequent organization of the collagen in the extracellular space. The basic 
transcription, post-translational modification and organization of collagen are as follows: 
1. The Col1a1 and Col1a2 genes are transcribed and the resulting mRNA is translated then 
transported to the endoplasmic reticulum (ER). 2. Once in the ER, the signal peptide is 
removed, the lysine and proline residues get additional hydroxyl groups added to them, 
glycosylation of selected hydroxyl groups on lysine occurs, and finally the collagen chains 
assemble into triple helices (termed pro-collagen) then secreted into the extracellular space. 
3. Collagen peptidases cleave the ends of the non-helical ends of the procollagen molecule 
and lysyl oxidases act on certain amino acid groups on the collagen to form cross-links 
stabilizing the organization of the collagen matrix171.  
Multiple events during the transcription and post-translational modification of the 
collagen is confirmed by the use of the collagen mimetic peptide (CMP) used in my study. 
The CMP mimics the proline-hydroxyproline-glycine amino acid triplet motif present in 
the protein sequence. By the strong binding of the CMP to the abnormal bony matrix in the 
Hox11 conditional mutants (refer to Figure 3.4J), I can confirm that a collagen matrix is 
being secreted by the mutant osteoblasts. This is further validated by the picrosirius red 
stain showing the haphazard organization of the collagen (refer to Figure 3.4). Due to the 
hydroxyproline motif in the CMP, the addition of the hydryoxyl groups is also confirmed. 
The CMP is only able to bind collagen strands and not to those assembled into triple 
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helices, which indicates that the collagen secreted by the mutant osteoblasts were either 
never assembled into normal triple helices or Hox genes facilitate the production of proteins 
that stabilize the organization of the collagen matrix (e.g. lysyl oxidase). In either case, 
further future investigation will be required to address these questions (explained in detail 
in Future Directions section below).  
Another course of action Hox11 may be involved in is the regulation of integrins. 
Integrins are the principle receptors for animal cells to facilitate binding to their 
extracellular surroundings. It has been shown that  Hoxa11 acts upstream to promote the 
expression of Integrin a8 in the developing kidney172 and expression of a dominant 
negative form of Integrin b1 in mature osteoblasts show skeletal phenotypes reminiscent 
of our Hox11 conditional mutant173. Blocking integrin-mediated adhesion of osteoblasts 
using mimetic peptides also led to abnormal bone formation174.  A wide variety of integrins 
including Integrin a1, a2, a3, a5, a6, aV, b1, b3, b4, and b5 have been identified to be 
expressed in MSCs and osteoblasts175,176. Matrix stiffness highly impacts the 
differentiation of MSCs indicating that the ability for cells to sense their environment plays 
a critical role in their differentiation (reviewed by 177). Taken together, this supports the 
hypothesis that the MSCs’ ability to bind to the extracellular matrix primarily through 
integrins highly influences the differentiation of progenitor cells. In-depth investigation 
into whether Hox11 regulates integrin expression that in turn affects the differentiation of 
skeletal stem cells would be an interesting next step (detailed in Future Directions section 
below).  
Overall, the definitive data presented in my study shifts the prevalent belief that 
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Hox gene function in the skeleton is largely restricted to developmental stages. Further, 
results from my study clearly demonstrate that Hox genes regulate the proper 
differentiation and subsequent maturation of osteoblasts in vivo. Future studies 
interrogating the specific mechanisms involved in Hox regulation of skeletal stem cell 
differentiation will reveal critical information to the still enigmatic molecular mechanism 
of Hox genes.  
Future directions 
Identifying downstream molecular targets of Hox11 
 Despite many decades since the discovery of Hox genes and the plethora of genetic 
studies revealing their critical function, their downstream targets still remain unclear. The 
lack of reliable Hox antibodies complicates this issue. Many studies have made an effort 
to interrogate this question by expressing tagged versions of Hox proteins into cells 
followed by chromatin immunoprecipitation (ChIP), performing microarrays, and utilizing 
enhancer-trap systems125,178–181. Many targets have been revealed by these endeavors, 
however the artificial nature of transfecting tagged Hox proteins complicates the 
interpretation of the results and targets identified by microarray may not necessarily be 
directly regulated by Hox proteins. Therefore, a comprehensive list of Hox protein targets 
are still lacking. The ideal system for identifying Hox downstream targets would involve 
the production of Hox proteins under their endogenous regulatory elements and their 
subsequent binding in vivo. To address this issue, I have generated two mouse models 
where a 3X FLAG peptide has been inserted into the 3’ end of the Hoxa11 and Hoxd11 
loci (refer to Appendix I). This allows for the identification of the downstream targets of 
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Hox11 in vivo with minimal disruption to their transcriptional regulatory machinery.  
 The expression of both genes has been verified by a FLAG antibody and the 
expression pattern recapitulates that seen by the Hoxa11eGFP reporter allele and Hoxd11 
in situ hybridization in embryonic limbs (Figure 4.1A-D).  The next imperative 
verification is proper function of the tagged Hox11 proteins. To that point, heterozygotes 
from the Hoxa11-3XFLAG and Hoxd11-3XFLAG colonies are currently being bred 
together to ultimately generate homozygotes for all four Hox11 alleles. Animals with the 
genotype Hoxa113XFLAG/3XFLAG; Hoxd113XFLAG/3XFLAG will be used to assess whether the 
insertion of the 3X FLAG peptide has negatively impacted the genes. If the 3X FLAG 
insertion rendered the alleles non-functional, then Hoxa113XFLAG/3XFLAG; 
Hoxd113XFLAG/3XFLAG animals would be expected to display Hox11 null phenotypes (i.e. 
malformation of zeugopod skeleton).  
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Figure 4.1. Expression pattern validation of Hoxa11-3X FLAG and Hoxd11-3X FLAG 
alleles. (A) Expression pattern of Hoxa11 (green) at E13.5 is shown in the zeugopod region 
with the condensing cartilage anlage stained with Sox9 (red). Figure adapted from 
Swinehart et al. (2013)88. (B) Hoxd11 expression pattern (blue color) is detected by in situ 
hybridization in E12.5 limbs. Figure adapted from Fabre et al. (2018)182. (C) Compare to 
Hoxa11eGFP expression pattern in (A) and note similar pattern. Expression pattern shown 
in E13.5 limbs from Hoxa11-3XFLAG animals detected by FLAG antibody (image 
courtesy of Lauren Koch). (D) Compare to Hoxd11 expression pattern in (B) and note 
similar pattern. Expression pattern shown in E12.5 limbs from Hoxd11-3XFLAG animals 
detected by FLAG antibody (image courtesy of Lauren Koch).  
 
 Once proper function of the Hox11 paralogs have been confirmed, subsequent ChIP 
experiments will identify DNA sites bound by the Hox11 proteins. However, the ChIP 
experiments alone will be insufficient to reveal targets of Hox11 proteins as mere binding 
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does not necessarily indicate transcriptional regulation. Hox genes have a rather generic 
TAAT core binding motif that has little specificity in binding DNA183–185. Therefore, 
performing RNA-sequencing of Hox11eGFP-expressing cells in control and Hox11 
conditional mutants to identify differentially regulated mRNA and compare them to the 
bound sites from the ChIP experiments will reveal a more comprehensive list of 
downstream targets of Hox11 proteins.  
 Generating mouse models with different tags for the distinct Hox11 paralogs will 
add more depth to understanding the downstream targets of Hox11. For example, one can 
generate a hemagglutinin (HA)-tagged Hoxd11 and myc-tagged Hoxc11 to use with the 
3XFLAG-tagged Hoxa11. These animals can be generated using the same approach as the 
3X FLAG-tagged Hoxa11 and Hoxd11 animals (refer to Appendix I). Both the HA and 
myc tag have a shorter peptide sequence compared to the 3X FLAG anticipating relatively 
simple generation of the animals. The different tags can be used in conjunction to 
interrogate whether Hox genes within the same paralogous group bind to the same or 
different targets. Intriguingly, Hoxc11 is only expressed in the hindlimbs. Examining the 
differences in binding sites between Hoxc11 compared to that of Hoxa11 or Hoxd11 would 
reveal interesting insights into the potential distinct mechanism of Hoxc11 function in 
forelimbs and hindlimbs. Again, performing RNA-seq coinciding with the ChIP 
experiments will allow for the direct correlation of binding and transcriptional regulation.  
 As mentioned previously, the generic and simple binding motif of Hox proteins 
does not coincide with the highly specific functions they perform in vivo. The binding of 
co-factors have been found to increase Hox proteins’ binding specificity. Extradenticle 
(Exd) and homothorax (Hth) in Drosophila and their vertebrate homologs Pbx and Meis 
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proteins, interact with Hox proteins to form a tripartite complex186–189. The presence of 
these cofactors confers longer binding consensus for Hox proteins and there is evidence 
for differential binding specificity of different Hox proteins190–192. In some cases, the Hox-
cofactor complex can change the binding preference of Hox protein providing “latent 
specificity”193. These findings suggest that the binding of co-factors, establishing a 
complex is critical in DNA binding specificity. Therefore, in order to further comprehend 
the molecular mechanisms of Hox proteins, it would be important to identify co-factors 
that are part of the Hox-binding partner complex. To address this question, the 3X FLAG 
animals that are already available or the HA- or myc-tagged theoretical mouse models can 
be used to perform IP-mass spectrometry experiments to identify potential binding partners 
of Hox proteins.  
 Characterization of the potential targets of Hox11 could be identified by some 
follow-up studies from my work with the Hox11 conditional mutant phenotype observed. 
As mentioned in the Summary of significant findings section, the mutant osteoblasts are 
capable of secreting a collagen matrix. However, whether the collagen that is secreted has 
a malformed structure or whether there is a lack of proteins that assist subsequent collagen 
organization and maturation was not determined. The structure of collagen molecules can 
be determined by Raman spectroscopy that uncovers biochemical information regarding 
the collagen molecules194. By comparing Raman spectroscopy results of collagen 
molecules from the control and Hox11 conditional mutant bones may provide insight into 
pinpointing the defects found in the collagen molecules. Additionally, performing western 
blot analyses probing for proteins such as lysyl oxidases that are important in the 
organization of extracellular collagen would also offer further comprehension in potential 
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mechanisms of Hox function at the molecular level.  
 In regard to addressing Hox11 regulation of integrins, the first experiment to 
perform would be an adhesion assay to determine whether cell adhesion is altered in the 
Hox11 conditional mutant cells. Once an adhesion defect is confirmed, qRT-PCR as well 
as western blot analysis examining integrins that are known to be expressed in skeletal 
stem cells as well as osteoblasts that include Integrin a1, a2, a3, a5, a6, aV, b1, b3, b4, 
and b5 will need to be examined to identify specific integrins molecule controlled by 
Hox11. These results can be verified by the RNA-seq and ChIP data, if available. Further, 
rescue experiments by either transfection or stimulatory antibodies195 on the isolated Hox11 
mutant cells can be performed to validate these findings.  
Hox function in mesenchymal stem cells (MSCs) or skeletal stem cells 
An important function for adult MSCs is their ability to contribute to fracture repair. We 
have previously shown that the Hox11-lineage extensively contributes to the fracture 
callus147. Examining Hox requirement during adult fracture injury repair using the Hox11 
conditional mutant would provide further insight into adult Hox function in skeletal stem 
cells. Preliminary studies I have performed show that while the fracture callus forms and 
initial cartilage differentiation, identified by Sox9 expression, occurs in the Hox11 
conditional mutants at 10 days-post-fracture (DPF), there is a significant delay in fracture 
repair as the fracture gap has not been resolved even at 6 weeks-post-fracture (WPF) 
(Figure 4.1). As the timing of chondrocyte and osteoblast appearance within the fracture 
callus is well characterized, deleting Hox at various stages throughout the repair process 
would further refine Hox-mediated regulation of MSC differentiation at adult stages. 
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Scrutinizing stage-specific Hox function in the skeleton would be an interesting 
follow-up study to my work by using the conditional allele to delete Hox function during 
embryonic skeletal development and postnatal skeletal growth. While embryonic loss-of-
function has clearly established that Hox genes impart region-specific function that 
differentially controls skeletal patterning and morphology, results from my study raise the 
question of whether differential Hox gene function continues to be conveyed in a region-
specific manner or whether all Hox function is similar once the skeleton has been 
established. The experiment suggested above will further reveal intriguing information 
regarding the function of Hox genes in a stage-specific context.  
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Figure 4.2. Hox11 conditional mutants can initiate fracture repair but exhibit a 
significant lag in bridging the fracture gap. Controls (Hoxa11eGFP/-; Hoxd11loxP/loxP)  and 
Hox11 conditional mutants (ROSACreERT2/+; Hoxa11eGFP/-; Hoxd11loxP/loxP) animals were 
fed on tamoxifen chow at 8-10 weeks of age and their ulna were fractured after a 1-month 
chase starting from deletion. (A, B) At 10 days-post-fracture (10DPF) both control and 
Hox11 conditional mutants form a fracture callus around the fracture site with an expansion 
of Hoxa11eGFP-expressing cells (green). Solid white line outlines the fracture callus. 
Dashed white lines outline the cortical bone (CB). (C, D) Sox9-expressing early cartilage 
cells (red) are present within both the control and Hox11 conditional mutant  fracture 
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calluses. (E, F) SafO-fast green stain that labels cartilage and bone, respectively, reveals 
that the fracture callus has not been resolved in the Hox11 conditional mutants and the 
fracture gap has not been bridged. Red dashed line marks the fracture site.  
 
Previous work from our lab suggests that the maintenance of skeletal stem cells is 
independent of Hox function as the Hoxa11eGFP-expressing MSCs are present in the 
Hox11 compound mutant at comparable numbers to that of control86 and Hoxa11eGFP-
expressing cells are found in the zeugopod skeleton of the Hox11 conditional mutant bones 
at 1-year of age (following a 10-month chase, refer to Sup Figure 3.3). However, a careful 
analysis has not been performed. Performing flow cytometry on the Hox11 conditional 
mutant zeugopod bones and carefully quantifying the numbers of Hox11-expressing MSCs 
at various time points following the deletion of Hox11 function, examining other sub-
populations of MSCs (mentioned in Chapter II) and how they compare between control 
and conditional mutants may provide additional functions for Hox genes in MSCs such as 
maintenance of quiescence, promoting self-renewal, cross-talk with other MSC 
populations etc. Furthermore, the physical requirement for Hox-expressing cells within the 
skeleton has not been examined. DTR-mediated ablation of Hox-expressing cells at various 
time points throughout skeletal development, growth, and homeostasis may reveal 
unforeseen consequences that could provide intriguing insight into the function of Hox-
expression cells.  
To date, work in our laboratory has focused on Hox11 as a model for global Hox 
function. This has led to intriguing and novel insights into Hox function. However, it still 
remains to be determined whether the findings from our laboratory using Hox11 can be 
applied and broadened to other Hox paralogous groups. Several groups have reported that 
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fibroblasts extracted from distinct physiological locations retain region-specific Hox 
expression established during development68,69,196. Previous work from our lab extended 
these analyses to bone marrow stromal cells that were isolated from the adult zeugopod 
and stylopod to examine Hox9-11 expression using qRT-PCR. It was confirmed that 
regional expression of Hox genes established during embryogenesis is maintained into 
adult stages, specifically in progenitor-enriched MSCs86. Generating a fluorescent reporter 
knock-in allele for a different Hox paralogs expressed at various axial levels followed by 
careful characterization mirroring that performed with the Hoxa11eGFP allele assessing 
the MSC characteristics of other Hox-expressing cells would broaden our findings. This 
can be taken further by generating inducible CreERT2 alleles for the corresponding Hox 
paralogs to determine in vivo regional contribution to the skeleton and generating 
conditional alleles examining the consequences of conditional deletion of Hox function 
similar to that of my study in Chapter III. Information gathered from these kinds of future 
studies will determine whether other Hox paralogs share similar cellular mechanisms and 
functions. 
Overall, these studies will provide unprecedented insight into the cellular function 
and molecular mechanism of Hox genes. These future directions will provide a strong 
foundation to address questions that are outside the current scope of this thesis including 
molecular targets of Hox genes and the global nature of Hox function in regional skeletal 
MSC populations. Results from these experiments will also have a significant impact on 
their potential therapeutic use considering the potential functional differences between 
region-specific MSC populations. Future studies will expand our understanding 
of Hox function in skeletal biology, broaden our knowledge regarding Hox function in 
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skeletal MSCs, and also contribute important new insight in skeletal MSC biology. 
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APPENDIX I 
Generation of Hoxa11-3XFLAG and Hoxd11-3XFLAG by 
Cas9/CRISPR Genetic Engineering 
 Cas9/CRISPR genetic engineering was used to insert the synthetic 3X FLAG 
peptide into the 5’ end of the Hoxa11 and Hoxd11 loci. We searched for guide RNAs that 
cut closest to the translational start site (ATG) with the minimum number of amino acids 
between the ATG and guide RNA cut site (Appx Figure 5.1A and 5.2A). The donor 
sequence was designed so that the 3X FLAG sequence was present between the guide RNA 
cut site and downstream PAM site eliminating the possibility of unwanted the Cas9 
nuclease targeting to the donor sequence or recombined allele. This editing strategy was 
carefully designed not disrupt the surrounding sequence around both loci to keep all 
endogenous regulatory elements intact. Further, a Gly-Ser-Gly flexible bridge was inserted 
immediately downstream of the 3X FLAG sequence to relieve any conformation strain that 
may result from the FLAG peptide in the final protein product.  
 7 out of 85 live births for the Hoxa11-3XFLAG and 10 out of 61 live births for the 
Hoxd11-3XFLAG founder animals (F0) were confirmed to produce the correct size band 
for 3XFLAG insertion assessed by PCR (Appx Figure 5.1B and 5.2B). Precise and in-
frame targeting was confirmed by sanger sequencing. 3 out of the 7 founders for the 
Hoxa11-3XFLAG and 4 out of the 10 for the Hoxd11-3XFLAG founders were confirmed 
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to have perfectly targeted insertion of the 3XFLAG peptide (Appx Figure 5.1C and 5.2C). 
Founder #541 for Hoxa11-3XFLAG and founder #23 for Hoxd11-3XFLAG were chosen to 
establish subsequent colonies. The founders were bred back to C57/Bl6 wildtype animals 
for two generations to generate heterozygotes.  
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Appendix Figure 5.1. Generation of Hoxa11-3XFLAG allele via Cas9/CRISPR genetic 
engineering. (A) Top panel: cartoon schematic of the Hoxa11 locus and approximate 
position of target guide RNA for 3XFLAG insertion. Green underline highlights 
transcription start site and gray highlight marks the PAM sequence of the guide RNA. 
Bottom panel: DNA sequence of the theoretical Hoxa11-3XFLAG allele. Green highlight: 
transcription start site (ATG). Pink highlight: 3X FLAG peptide sequence. Yellow 
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highlight: Gly-Ser-Gly flexible bridge sequence. (B) PCR analysis using P1 and P2 (red 
arrows) that are upstream and downstream from the gRNA cut site revealed 7 animals (blue 
asterisk) with the expected band size for a 3XFLAG insertion (317bp). (C) Sequence 
chromatogram from the #541 showing correct, in-frame insertion of the 3X FLAG peptide 
into the Hoxa11 locus. Green highlight: transcription start site (ATG). Pink highlight: 3X 
FLAG peptide sequence. Yellow highlight: Gly-Ser-Gly flexible bridge sequence. 
 
 
 
Appendix Figure 5.2. Generation of Generation of Hoxd11-3XFLAG allele via 
Cas9/CRISPR genetic engineering. (A) Top panel: cartoon schematic of the Hoxd11 
		 125	
locus and approximate position of target guide RNA for 3XFLAG insertion. Green 
underline highlights transcription start site and gray highlight marks the PAM sequence of 
the guide RNA. Bottom panel: DNA sequence of the theoretical Hoxd11-3XFLAG allele. 
Green highlight: transcription start site (ATG). Pink highlight: 3X FLAG peptide sequence. 
Yellow highlight: Gly-Ser-Gly flexible bridge sequence. (B) PCR analysis using P1 and 
P2 (red arrows) that are upstream and downstream from the gRNA cut site revealed 7 
animals (blue asterisk) with the expected band size for a 3XFLAG insertion (450bp). (C) 
Sequence chromatogram from the #23 showing correct, in-frame insertion of the 3X FLAG 
peptide into the Hoxa11 locus. Green highlight: transcription start site (ATG). Pink 
highlight: 3X FLAG peptide sequence. Yellow highlight: Gly-Ser-Gly flexible bridge 
sequence. 
Materials and Methods 
Production of sgRNAs and Cas9 mRNA 
All guide sequences were cloned into the pT7-Guide Vector (Blue Heron Biotech, LLC). 
MEGAshortscript T7 kit (Life Technologies) was used to generate in vitro transcribed 
sgRNA’s from the pT7-Guide Vector and products were subsequently purified using the 
MEGAclear kit (Life Technologies). Using the pT7-Cas9-Nuclease vector (gift from Dr. 
Moises Mallo), Cas9 mRNA was in vitro transcribed using the mMESSAGE mMACHINE 
T7 ULTRA kit (Life Technologies) and purified using the MEGAclear kit (Life 
Technologies).  
Donor oligos 
Donor oligos were purchased from Integrated DNA Technologies (IDT) as Megamer® 
Single-stranded DNA fragments. The total length of the donor oligo was kept at 200bp. 
Thus, the homology sequence on either side was approximately 50bp.  
Zygote injection 
Zygote injections were performed as previously described with minor modifications145. 
C57BL/6 female mice were super-ovulated and mated with C57Bl/6 male mice in order to 
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collect embryos of one-cell stage for microinjection. CRISPR reagents were microinjected 
at the following concentrations: Cas9 mRNA (100ng/μL), sgRNA (50ng/μL), and donor 
oligo (25ng/μL). Freshly injected eggs were transferred into pseudopregnant females and 
resulting progeny were initially screened for potential recombination events via PCR. 
 
Confirmation of Hoxa11-3XFLAG targeting  
85 live births were recovered from the microinjections and initial screening for 
3XFLAG targeting was performed by PCR. Approximate location of all primers is 
indicated in Appx Figure 5.1A. 
Primers (Wildtype 200bp, 3XFLAG targeted 317bp) 
Forward: 5’ – GTC ACA TGA CCA GCA CCT CC – 3’ 
Reverse: 5’ – AGT ATG TCA TTG GGC GCG AA – 3’ 
 
 Correct targeting was confirmed by sanger sequencing using the same primers used 
for PCR indicated above. 
Confirmation of Hoxd11-3XFLAG targeting 
 61 live births were recovered from the microinjections and initial screening for 
3XFLAG targeting was performed by PCR. Approximate location of all primers is 
indicated in Appx Figure 5.2A.  
Primers (Wildtype 369bp, 3XFLAG targeted 450bp) 
Forward: 5’ – ACG TGA CAT AAT TAC CAC CAG AA – 3’ 
Reverse: 5’ – CAG GCC GTA GTC GCG AAA – 3’ 
 
 Correct targeting was confirmed by sanger sequencing using the same primers used 
for PCR indicated above.  
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